<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Neurol Disord</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Neurol Disord</journal-id><journal-id journal-id-type="publisher-id">TAN</journal-id><journal-id journal-id-type="hwp">sptan</journal-id><journal-title-group><journal-title>Therapeutic Advances in Neurological Disorders</journal-title></journal-title-group><issn pub-type="ppub">1756-2856</issn><issn pub-type="epub">1756-2864</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30083232</article-id><article-id pub-id-type="pmc">6066814</article-id><article-id pub-id-type="doi">10.1177/1756286418789854</article-id><article-id pub-id-type="publisher-id">10.1177_1756286418789854</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Anti-inflammatory treatments for stroke: from bench to
bedside</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Drieu</surname><given-names>Antoine</given-names></name><aff id="aff1-1756286418789854">Pathophysiology and Imaging of Neurological
Disorders, Normandy University, Caen, France</aff></contrib><contrib contrib-type="author"><name><surname>Levard</surname><given-names>Damien</given-names></name><aff id="aff2-1756286418789854">Pathophysiology and Imaging of Neurological
Disorders, Normandy University, Caen, France</aff></contrib><contrib contrib-type="author"><name><surname>Vivien</surname><given-names>Denis</given-names></name><aff id="aff3-1756286418789854">Pathophysiology and Imaging of Neurological
Disorders, Normandy University, Caen, France Pathophysiology and Imaging of
Neurological Disorders, Centre Hospitalier Universitaire de Caen, Caen,
France</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6120-4053</contrib-id><name><surname>Rubio</surname><given-names>Marina</given-names></name><xref ref-type="corresp" rid="corresp1-1756286418789854"/><aff id="aff4-1756286418789854">Pathophysiology and Imaging of Neurological
Disorders, Normandy University, Boulevard Henri Becquerel BP 5229, Caen
Cedex, 14000, France</aff></contrib></contrib-group><author-notes><corresp id="corresp1-1756286418789854"><email>rubio@cyceron.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>11</volume><elocation-id>1756286418789854</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>So far, intravenous tissue-type plasminogen activator (tPA) and mechanical
removal of arterial blood clot (thrombectomy) are the only available treatments
for acute ischemic stroke. However, the short therapeutic window and the lack of
specialized stroke unit care make the overall availability of both treatments
limited. Additional agents to combine with tPA administration or thrombectomy to
enhance efficacy and improve outcomes associated with stroke are needed.
Stroke-induced inflammatory processes are a response to the tissue damage due to
the absence of blood supply but have been proposed also as key contributors to
all the stages of the ischemic stroke pathophysiology. Despite promising results
in experimental studies, inflammation-modulating treatments have not yet been
translated successfully into the clinical setting. This review will (a) describe
the timing of the stroke immune pathophysiology; (b) detail the immune responses
to stroke sift-through cell type; and (c) discuss the pitfalls on the
translation from experimental studies to clinical trials testing the therapeutic
pertinence of immune modulators.</p></abstract><kwd-group><kwd>clinical trial</kwd><kwd>immunomodulatory drugs</kwd><kwd>inflammation</kwd><kwd>stroke models</kwd><kwd>translation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-1756286418789854"><title>Introduction</title><p>Every year, 15 million people worldwide suffer a stroke. Of these, 5 million die and
another 5 million are left permanently disabled, placing a burden on family and
community (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf?ua=1">http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf?ua=1</ext-link>).
In the United States a stroke event happens every 40 seconds, and every 4 minutes,
someone dies of stroke (American Stroke Association). Ischemic stroke is provoked by
an arterial occlusion in the brain that leads to the rapid death of the brain tissue
irrigated by that particular artery. So far, intravenous tissue-type plasminogen
activator (tPA) is the only available pharmacological agent for acute ischemic
stroke, but this agent is frequently underutilized due to its limited therapeutic
window (4.5 h) and increased risk of intracerebral hemorrhage. Recently, mechanical
thrombectomy has demonstrated beneficial effects on ischemic stroke in selected patients<sup><xref rid="bibr1-1756286418789854" ref-type="bibr">1</xref></sup> and has become the standard of care for patients with large-vessel occlusion
up to 24 h of stroke onset.<sup><xref rid="bibr2-1756286418789854" ref-type="bibr">2</xref>,<xref rid="bibr3-1756286418789854" ref-type="bibr">3</xref></sup>
Additional agents to combine with tPA administration or thrombectomy to improve
efficacy and ameliorate outcomes associated with stroke are needed, in particular,
for those patients not eligible for thrombolysis or thrombectomy, or with no access
to specialized stroke unit care. Easily administrable agents reducing tissue damage
even modestly would drastically decrease the burden of stroke on society and would
ameliorate patient outcomes and quality of life.<sup><xref rid="bibr4-1756286418789854" ref-type="bibr">4</xref></sup></p><p>Stroke-induced inflammatory processes, which include mechanisms of innate and
adaptive immunity, are a response to tissue damage due to the absence of blood
supply but have also been proposed as key contributors to all the stages of the
ischemic stroke pathophysiology.<sup><xref rid="bibr5-1756286418789854" ref-type="bibr">5</xref></sup> However, despite promising results in experimental studies,
inflammation-modulating treatments have not yet been translated successfully into
the clinical setting. This review will focus on the innate and adaptive immune
responses participating in ischemic brain injury and their impact on tissue damage
and repair in both experimental models of stroke and available clinical data. It has
been structured in three parts: a first part describing the timing of the stroke
pathophysiology from an immunological point of view (<xref ref-type="fig" rid="fig1-1756286418789854">Figure 1</xref>); a second part detailing the immune
responses to stroke sift-through cell type; and a third part discussing the pitfalls
on the translation from preclinical to clinical stroke research of immunomodulating
therapeutic agents.</p><fig id="fig1-1756286418789854" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Immune reactions after ischemic stroke.</p><p>(a) In the intact brain, the functional unit formed by tightly jointed ECs
and astrocytic endfeet constitute the BBB, a strong protective blood&#x02013;tissue
barrier from pathogens. Immune cells circulate freely in the blood, and in
the brain parenchyma, resting microglia survey the environment with their
processes. (b) A few minutes after stroke onset, the BBB is disrupted and
local ECs are activated. The tight junctions between ECs disappear and
activated ECs express CAMs. This allows white cell rolling and adhesion at
the luminal side of the blood vessel and then transmigration from the
vascular compartment to the brain parenchyma. Once infiltrated in the
tissue, neutrophils secrete pro-inflammatory factors that will recruit
monocytes/macrophages, and later lymphocytes to the parenchyma. After
stroke, microglia switches from a resting form to an activated state,
adopting a phagocytic phenotype and secreting pro-inflammatory factors.</p><p>BBB, blood&#x02013;brain barrier; CAM, cellular adhesion molecule; EC, endothelial
cell.</p></caption><graphic xlink:href="10.1177_1756286418789854-fig1"/></fig></sec><sec id="section2-1756286418789854"><title>Timeline of inflammatory events after stroke</title><p>Basically, inflammatory responses after stroke can be decomposed in three phases.<sup><xref rid="bibr5-1756286418789854" ref-type="bibr">5</xref></sup> The acute phase (first hours after stroke onset) corresponds to the clearing
of dead cells mainly by resident phagocytic cells such as microglia/macrophages and
a first entry of leukocytes, mainly neutrophils. The subacute phase (first days
after stroke) corresponds to resolution of inflammation. The late phase (days and
weeks after stroke) corresponds to tissue repair by astrocytes and microglia (glial
scar).</p><sec id="section3-1756286418789854"><title>The acute phase of stroke: tissue injury, microglial and endothelial
activation</title><p>The arterial occlusion at the origin of ischemic stroke leads to deprivation of
oxygen and nutrients that are essential for neuronal survival, leading to rapid
neuronal death in the core of the lesion site only minutes after stroke onset.
The absence of blood supply into the tissue is followed by a cascade of events
starting with a reduction in cellular adenosine triphosphate (ATP) that is
required to maintain ionic gradients. The disruption of ionic gradients leads to
an influx of Na<sup>+</sup> and Ca<sup>2+</sup>, cellular depolarization and
release of neurotransmitters, including the excitatory neurotransmitter glutamate.<sup><xref rid="bibr6-1756286418789854" ref-type="bibr">6</xref></sup> As energy-dependent removal of glutamate is impaired, glutamate
accumulation leads to overactivation and opening of monovalent ion channels
followed by water influx, thus resulting in cellular swelling and death.<sup><xref rid="bibr7-1756286418789854" ref-type="bibr">7</xref></sup> Dying neurons at the core of the lesion express free radicals,
damage-associated molecular patterns (DAMPs) and high-mobility group box 1
(HMGB1) protein that lead to inflammatory reactivity by microglia. Edaravone, a
free radical scavenger, has shown beneficial properties in stroke patients with
large-vessel occlusion, especially when combined with recombinant tissue-type
plasminogen activator, but not in combination with thrombectomy.<sup><xref rid="bibr8-1756286418789854" ref-type="bibr">8</xref></sup> Activated microglia adopt a pro-inflammatory status, expressing
pro-inflammatory cytokines [interleukin 1 (IL-1), IL-6] that are released into
blood circulation.<sup><xref rid="bibr9-1756286418789854" ref-type="bibr">9</xref></sup></p><p>Pro-inflammatory cytokines exacerbate endothelial cell (EC) activation
contributing to leukocyte rolling, adhesion and infiltration in brain tissue.
Leukocytes start to roll on the vessel wall with the help of selectins expressed
by activated EC. After rolling, leukocytes strongly adhere to the vessel wall by
strong links with intercellular adhesion molecule (ICAM-1) and vascular cell
adhesion molecule (VCAM-1).<sup><xref rid="bibr10-1756286418789854" ref-type="bibr">10</xref>,<xref rid="bibr11-1756286418789854" ref-type="bibr">11</xref></sup> Into the brain, there is
almost no way for leukocytes to pass through the blood&#x02013;brain barrier (BBB) in
nonpathological conditions.<sup><xref rid="bibr12-1756286418789854" ref-type="bibr">12</xref></sup> However, the BBB integrity is disrupted after stroke onset and tight
junctions between EC disappear, allowing leukocyte infiltration into the injured
brain tissue.<sup><xref rid="bibr13-1756286418789854" ref-type="bibr">13</xref></sup> Clinical data and experimental models of stroke have shown that
neutrophils infiltrate within hours of stroke onset.<sup><xref rid="bibr14-1756286418789854" ref-type="bibr">14</xref>,<xref rid="bibr15-1756286418789854" ref-type="bibr">15</xref></sup></p></sec><sec id="section4-1756286418789854"><title>The subacute phase: resolution of inflammation</title><p>In the first days after stroke, different leukocyte populations, including
macrophages and lymphocytes, infiltrate the brain.<sup><xref rid="bibr14-1756286418789854" ref-type="bibr">14</xref>,<xref rid="bibr15-1756286418789854" ref-type="bibr">15</xref></sup> The infiltration of
leukocyte subpopulations differs among murine permanent and transient mechanical
focal cerebral ischemia models<sup><xref rid="bibr16-1756286418789854" ref-type="bibr">16</xref></sup> and the inflammatory response seems to be more pronounced after permanent
electrocoagulatory middle cerebral artery occlusion (MCAO) compared with 30-min
and 90-min transient mechanical vascular occlusion (TMVO).<sup><xref rid="bibr16-1756286418789854" ref-type="bibr">16</xref></sup> Descriptive data on the timeline inflammatory responses in
thrombus-induced experimental stroke models are missing.</p><p>Preclinical studies performed on TMVO models of ischemic stroke have shown a
secondary injury after reperfusion (i.e. cerebral ischemia/reperfusion injury).
While mechanical thrombectomy also promotes rapid reperfusion, it does not seem
to provoke such a secondary injury in patients with proximal
middle-cerebral-artery or internal-carotid-artery occlusion and a penumbral
region of tissue (i.e. a brain region that is ischemic but not infarcted yet,
which is therefore salvageable). This is probably due to a better collateral
circulation and slower infarct growth in these patients and is associated to a
higher proportion of good functional outcomes at 3 months after stroke, compared
with patients with little or no penumbra, even when performed late (16&#x02013;24 h)
after stroke onset.<sup><xref rid="bibr2-1756286418789854" ref-type="bibr">2</xref>,<xref rid="bibr3-1756286418789854" ref-type="bibr">3</xref>,<xref rid="bibr17-1756286418789854" ref-type="bibr">17</xref></sup> In the DEFUSE 2 study, patients with little or no penumbra
had a greater lesion growth despite reperfusion. This greater lesion growth
could be the result of reperfusion-related edema based on the larger infarct
core volumes in the no penumbra group.<sup><xref rid="bibr17-1756286418789854" ref-type="bibr">17</xref></sup></p></sec><sec id="section5-1756286418789854"><title>The late phase: tissue repair and glial scar</title><p>Neuroinflammation is also considered necessary for the reparation phase that
persists after the initial brain insult.<sup><xref rid="bibr18-1756286418789854" ref-type="bibr">18</xref><xref rid="bibr19-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr20-1756286418789854" ref-type="bibr">20</xref></sup> This phase aims at
restoring tissue integrity and involves matrix remodeling, neurogenesis, axon
sprouting, dendritogenesis and oligodendrogenesis.<sup><xref rid="bibr21-1756286418789854" ref-type="bibr">21</xref></sup> All these processes are common to acute brain injuries (including
ischemia, hemorrhage, and trauma), neuroinflammatory (including multiple
sclerosis) and neurodegenerative disorders,<sup><xref rid="bibr22-1756286418789854" ref-type="bibr">22</xref></sup> that initiate an extensive glial response known as reactive gliosis.
Reactive gliosis involves an enhanced expression of specific markers, such as
various extracellular matrix molecules (ECM) like chondroitin sulfate
proteoglycans (CSPG) and glial fibrillary acidic protein (GFAP) for astrocytes.
Glial scar formation is crucial for sealing the lesion site to remodel the
injured tissue, in order to spatially and temporally control the local immune
response and revascularization of blood capillaries. Nonetheless, the glial scar
also acts as an obstacle to axon regeneration and thus avoids the recovery of
central nervous system (CNS) function in the chronic phase after stroke.
Experimental studies on the glial response to ischemic stroke have been
performed in animal models using variations of permanent or focal transient MCAO
and photothrombosis.<sup><xref rid="bibr23-1756286418789854" ref-type="bibr">23</xref><xref rid="bibr24-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr25-1756286418789854" ref-type="bibr">25</xref></sup> The human
brain after ischemic injury seems to share similar properties to these
experimental models of stroke.<sup><xref rid="bibr26-1756286418789854" ref-type="bibr">26</xref></sup></p></sec></sec><sec id="section6-1756286418789854"><title>Immunomodulating therapeutic strategies for stroke: sift-through cell
type</title><p>Clinical trials on stroke immunology have targeted both innate and adaptive immune
responses, by reducing microglial activation, inhibiting leukocyte or lymphocyte
migration to the brain parenchyma, and blocking the IL-1 receptor. The increasing
number of immunomodulatory treatments that are already established for other
indications in humans have provided a good opportunity to fast-track innovative
proof-of-concept trials in stroke. However, and despite promising preclinical
results, immunomodulatory drugs have not shown clear benefits in large clinical
trials on stroke. Another strategy has been the induction of hypothermia to reduce
inflammatory responses and apoptosis triggered after stroke (among other
mechanisms). Several trials have shown its safety and feasibility, alone or in
combination with thrombolysis;<sup><xref rid="bibr27-1756286418789854" ref-type="bibr">27</xref><xref rid="bibr28-1756286418789854" ref-type="bibr"/><xref rid="bibr29-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr30-1756286418789854" ref-type="bibr">30</xref></sup> however, its efficacy in the
treatment of ischemic stroke is still debatable, especially because of increased
pneumonia incidence and mortality in the hypothermia group.<sup><xref rid="bibr31-1756286418789854" ref-type="bibr">31</xref></sup> New clinical trials on the effects of the combination of
thrombolysis/thrombectomy plus hypothermia are ongoing.<sup><xref rid="bibr32-1756286418789854" ref-type="bibr">32</xref></sup>
<xref ref-type="fig" rid="fig2-1756286418789854">Figure 2</xref> summarizes the
results of clinical trials targeting the immune responses triggered after ischemic
stroke.</p><fig id="fig2-1756286418789854" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Summary of clinical trials targeting the immune responses triggered after
ischemic stroke.</p><p>CD11/CD18, LFA-1 for lymphocyte function-associated antigen 1; IL-1,
interleukin 1; rhIL1-Ra, recombinant human interleukin 1 receptor
antagonist; ICAM-1, intercellular adhesion molecule; VCAM-1, vascular cell
adhesion molecule; VLA-4, leukocyte very late antigen-4.</p></caption><graphic xlink:href="10.1177_1756286418789854-fig2"/></fig><sec id="section7-1756286418789854"><title>Microglial cells</title><sec id="section8-1756286418789854"><title>Pathophysiology</title><p>Microglial cells constitute 10&#x02013;15% of the brain cells and are the resident
mononuclear phagocytes of the brain parenchyma.<sup><xref rid="bibr33-1756286418789854" ref-type="bibr">33</xref></sup> As aforementioned, microglial response is one of the first steps of
the innate immune responses triggered after stroke. Microglial cells are in
close contact with neurons and constantly survey the environment with their processes.<sup><xref rid="bibr34-1756286418789854" ref-type="bibr">34</xref></sup> These cells can adopt a large spectrum of phenotypes ranging from
pro-inflammatory to anti-inflammatory and neuroprotective. At the acute
phase after stroke onset, microglial cells at the core of the lesion detect
DAMPs and HMGB1 <italic>via</italic> their receptors mainly belonging to the
Toll-like receptor (TLR) family.<sup><xref rid="bibr13-1756286418789854" ref-type="bibr">13</xref>,<xref rid="bibr35-1756286418789854" ref-type="bibr">35</xref><xref rid="bibr36-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr37-1756286418789854" ref-type="bibr">37</xref></sup> This ligand&#x02013;receptor
link leads to internalization of nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor (I&#x003ba;B) kinase into the nucleus and the
subsequent activation of the nuclear factor of kappa light chain enhancer of
activated B-cells (NF-&#x003ba;B) pathway and thus to the activation of microglial
cells. Also, loss of the constitutively expressed neuronal ligand CX3CL1
(fractalkine) after neuronal death results in enhanced microglial activation
through their receptors CX3CR1.<sup><xref rid="bibr38-1756286418789854" ref-type="bibr">38</xref></sup> Experimental models of both transient and permanent ischemic stroke
have shown an increase in the number of microglial cells on the ipsilateral
cortex in the first 24 h after stroke onset.<sup><xref rid="bibr14-1756286418789854" ref-type="bibr">14</xref>,<xref rid="bibr16-1756286418789854" ref-type="bibr">16</xref></sup> Once activated,
microglial cells express high levels of CD11b, CD45 and CD68 corresponding
to a phagocytic phenotype responsible for the clearance of cellular debris,<sup><xref rid="bibr9-1756286418789854" ref-type="bibr">9</xref></sup> as well as tumor necrosis factor and the pro-inflammatory
interleukins IL-1 and IL-6 that are released into blood circulation.<sup><xref rid="bibr9-1756286418789854" ref-type="bibr">9</xref></sup> IL-1 has been targeted to reduce further cerebral injury mediated by
inflammation. A meta-analysis showed that IL-1 receptor antagonist (IL-1Ra)
administration was associated with a 38.2 % reduction in mean infarct volume
across 16 published preclinical studies.<sup><xref rid="bibr39-1756286418789854" ref-type="bibr">39</xref></sup> In a phase II clinical study, recombinant human IL-1Ra (rhIL-1Ra;
anakinra) administered at hospital arrival has shown beneficial effects in
patients with cortical infarcts, with better clinical outcomes after 3
months in the treated group.<sup><xref rid="bibr40-1756286418789854" ref-type="bibr">40</xref></sup> However, the recently published results of a second phase II study on
the effect of subcutaneous IL-1Ra administration (SCIL-STROKE) has shown
that, in spite of a significant reduction in plasma inflammatory markers
associated with a worse outcome after ischemic stroke, IL-1Ra treatment was
not associated with a favorable outcome on modified Rankin Scale (mRS).<sup><xref rid="bibr41-1756286418789854" ref-type="bibr">41</xref></sup></p><p>Recently developed techniques of total microglial depletion have shown that
microglia seem essential to the limitation of stroke damages, since
microglia-depleted mice show larger infarct volumes than nondepleted mice.<sup><xref rid="bibr42-1756286418789854" ref-type="bibr">42</xref></sup></p></sec><sec id="section9-1756286418789854"><title>Therapeutic strategies targeting microglia</title><p>Minocycline, an anti-infective agent of the tetracycline family used for the
treatment of infections caused by a wide range of organisms, has been tested
for the treatment of stroke. It is highly lipophilic and crosses the
blood&#x02013;brain barrier. Minocycline, by acting through different pathways, is
able to inhibit microglial activation, decrease migration of T cells, reduce
neuronal apoptosis, block free radical production, decrease CNS expression
of chemokines and their associated receptors, and inhibit matrix
metalloproteinases, particulary matrix metalloproteinase-9.<sup><xref rid="bibr43-1756286418789854" ref-type="bibr">43</xref><xref rid="bibr44-1756286418789854" ref-type="bibr"/><xref rid="bibr45-1756286418789854" ref-type="bibr"/><xref rid="bibr46-1756286418789854" ref-type="bibr"/><xref rid="bibr47-1756286418789854" ref-type="bibr"/><xref rid="bibr48-1756286418789854" ref-type="bibr"/><xref rid="bibr49-1756286418789854" ref-type="bibr"/><xref rid="bibr50-1756286418789854" ref-type="bibr"/><xref rid="bibr51-1756286418789854" ref-type="bibr"/><xref rid="bibr52-1756286418789854" ref-type="bibr"/><xref rid="bibr53-1756286418789854" ref-type="bibr"/><xref rid="bibr54-1756286418789854" ref-type="bibr"/><xref rid="bibr55-1756286418789854" ref-type="bibr"/><xref rid="bibr56-1756286418789854" ref-type="bibr"/><xref rid="bibr57-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr58-1756286418789854" ref-type="bibr">58</xref></sup> In preclinical stroke
studies, minocycline ameliorated behavioral function and decreased lesion
volume and hemorrhagic transformation.<sup><xref rid="bibr44-1756286418789854" ref-type="bibr">44</xref><xref rid="bibr45-1756286418789854" ref-type="bibr"/><xref rid="bibr46-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr47-1756286418789854" ref-type="bibr">47</xref></sup> It did not alter the
fibrinolytic effect of rtPA<sup><xref rid="bibr46-1756286418789854" ref-type="bibr">46</xref></sup> and could enlarge the time window for thrombolysis.<sup><xref rid="bibr49-1756286418789854" ref-type="bibr">49</xref></sup> Two phase II clinical trials have shown minocycline to be safe and
potentially effective in acute ischemic stroke, alone or in combination with
tPA, when administered in the first 24 h after stroke onset and for 5
days.<sup><xref rid="bibr59-1756286418789854" ref-type="bibr">59</xref>,<xref rid="bibr60-1756286418789854" ref-type="bibr">60</xref></sup> However, a third pilot study performed in a small
sample of acute stroke patients has shown that minocycline administration in
the first 24 h was safe but not efficacious.<sup><xref rid="bibr43-1756286418789854" ref-type="bibr">43</xref></sup> The authors acknowledged that this third study was not powered to
identify reliably or exclude a modest but clinically important treatment
effect of minocycline.<sup><xref rid="bibr43-1756286418789854" ref-type="bibr">43</xref></sup> Larger clinical trials are thus needed to study the effect of
minocycline in stroke patients.</p><p>Recently, preclinical studies have focused also on the switch of microglial
cell phenotype from M1 to M2 as a potential target to improve stroke
outcome, by administering IL-33<sup><xref rid="bibr61-1756286418789854" ref-type="bibr">61</xref></sup> or IL-4.<sup><xref rid="bibr62-1756286418789854" ref-type="bibr">62</xref></sup></p></sec></sec><sec id="section10-1756286418789854"><title>Endothelial cells</title><sec id="section11-1756286418789854"><title>Pathophysiology</title><p>In the brain, the functional unit formed by tightly jointed ECs and
astrocytic endfeet constitute the BBB, a strong protective blood&#x02013;tissue
barrier against pathogens. A few minutes after stroke onset, the BBB is
disrupted, and local ECs are activated. <sup><xref rid="bibr63-1756286418789854" ref-type="bibr">63</xref>,<xref rid="bibr64-1756286418789854" ref-type="bibr">64</xref></sup> When activated, ECs
express cellular adhesion molecules (CAMs) which allow leukocyte rolling and
adhesion to the luminal side of the EC and eventually leukocyte
transmigration toward the brain parenchyma.<sup><xref rid="bibr5-1756286418789854" ref-type="bibr">5</xref></sup> After their activation, the first adhesion molecules expressed by ECs
are the selectins (E- and P-selectins). They are constitutively produced by
ECs and stored in Weibel-Palade bodies until EC activation. The initial
adhesive interactions between leukocytes and selectins expressed on the
luminal side of the venular endothelium are tethering (capture) and rolling.
These low-affinity (weak) interactions are subsequently strengthened as a
result of the sequential activation of different families of adhesion
molecules that are located on the surface of leukocytes and ECs.<sup><xref rid="bibr65-1756286418789854" ref-type="bibr">65</xref></sup> A few hours after stroke onset, ECs start to express the VCAM-1 and
the ICAM-1,<sup><xref rid="bibr63-1756286418789854" ref-type="bibr">63</xref>,<xref rid="bibr66-1756286418789854" ref-type="bibr">66</xref></sup> allowing leukocytes to adhere and remain stationary
on the vessel wall. Finally, ECs express the platelet endothelial cell
adhesion molecule (PECAM-1), responsible for leukocyte transmigration into
the brain parenchyma.<sup><xref rid="bibr11-1756286418789854" ref-type="bibr">11</xref></sup></p></sec><sec id="section12-1756286418789854"><title>Therapeutic strategies targeting selectins</title><p>Strategies for the blockade of CAMs through the intravenous injection of
antibodies have failed in ameliorating stroke outcome both in clinical and
preclinical trials.</p><p>Enlimomab, a murine ICAM-1 antibody, reduces leukocyte adhesion and infarct
size in experimental stroke studies.<sup><xref rid="bibr67-1756286418789854" ref-type="bibr">67</xref></sup> However, the clinical trial performed in stroke patients showed that
the administration of enlimomab within 6 h after stroke onset is not an
effective treatment for ischemic stroke and, indeed, significantly worsened
stroke outcome and increased adverse events.<sup><xref rid="bibr68-1756286418789854" ref-type="bibr">68</xref></sup> One of the possible explanations for this failure is the murine
origin of the injected antibody to stroke patients.<sup><xref rid="bibr69-1756286418789854" ref-type="bibr">69</xref></sup></p><p>Induction of mucosal tolerance to E-selectin to minimize inflammation and
risk of further cerebral insult has been tested in a phase I clinical trial,
but results have not been disclosed.<sup><xref rid="bibr70-1756286418789854" ref-type="bibr">70</xref></sup></p><p>L-selectin, a CAM located in the surface of leukocytes, has also been
targeted in an experimental stroke model in rabbits by using a humanized
monoclonal antibody (HuDREG200). This strategy, alone or in combination with
alteplase, failed to significantly ameliorate stroke outcome.<sup><xref rid="bibr71-1756286418789854" ref-type="bibr">71</xref></sup></p></sec></sec><sec id="section13-1756286418789854"><title>Neutrophils</title><sec id="section14-1756286418789854"><title>Pathophysiology</title><p>The principal role of neutrophils is to enhance leukocyte recruitment by
degranulation of their content, rich in cytokines/chemokines, proteolytic
enzymes and activated-complement system.<sup><xref rid="bibr72-1756286418789854" ref-type="bibr">72</xref></sup> The extent of neutrophil infiltration after stroke is still debated,
being described either limited to the perivascular space or infiltrating the
brain tissue in preclinical stroke models (permanent or mechanical transient
occlusion of the MCA) and human postmortem samples.<sup><xref rid="bibr73-1756286418789854" ref-type="bibr">73</xref><xref rid="bibr74-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr75-1756286418789854" ref-type="bibr">75</xref></sup></p><p>It was postulated that neutrophils could contribute to brain injury after
ischemic stroke by obstructing microvessel circulation, damaging endothelial
cells and ECM by hydrolytic enzymes and free radicals, promoting
intravascular thrombus formation together with platelet activation, and
releasing cytokines and chemotactic factors that could promote extension of
the inflammatory response.<sup><xref rid="bibr76-1756286418789854" ref-type="bibr">76</xref></sup></p></sec><sec id="section15-1756286418789854"><title>Therapeutic strategies targeting neutrophils</title><p>Preclinical and clinical studies aiming at blocking neutrophil infiltration
have targeted CD11/CD18 (LFA-1 for lymphocyte function-associated antigen
1), located at the surface of neutrophils, to prevent their adhesion to
ICAM-1 (expressed at the luminal surface of ECs). Preclinical studies have
shown that CD11/CD18 monoclonal antibodies are not beneficial in permanent
stroke models,<sup><xref rid="bibr77-1756286418789854" ref-type="bibr">77</xref>,<xref rid="bibr78-1756286418789854" ref-type="bibr">78</xref></sup> but are beneficial on a transient mechanical
ischemic stroke model.<sup><xref rid="bibr79-1756286418789854" ref-type="bibr">79</xref></sup> In spite of this, two clinical trials have been performed to prevent
neutrophil recruitment after stroke onset and have shown no beneficial
effect. On the HALT phase III trial, the humanized antibody Hu23F2G,
administered twice daily, appeared to produce an improvement in mRS score in
a phase II study. However, the sponsor terminated a subsequent phase III
study when a &#x02018;futility analysis&#x02019; advised that no benefit of the treatment
would occur if the study was completed. No public information regarding the
database, outcomes, safety issues, or relative number of adverse events has appeared.<sup><xref rid="bibr76-1756286418789854" ref-type="bibr">76</xref></sup> On the ASTIN (Acute Stroke Therapy by Inhibition of Neutrophils)
study, UK-279,276 (another CD18 antagonist) was administered within 6 h of
stroke symptom onset, but, similar to the HALT study, the trial was stopped
early due to futility.<sup><xref rid="bibr80-1756286418789854" ref-type="bibr">80</xref></sup></p></sec></sec><sec id="section16-1756286418789854"><title>Lymphocytes</title><sec id="section17-1756286418789854"><title>Pathophysiology</title><p>Adaptive immunity also plays an important role during stroke. Lymphocytes
consist of distinct subpopulations with diverse functions and can be
subdivided into two groups: pro- and anti-inflammatory lymphocytes. The
consequences of the adaptive immune response on ischemic stroke are still
debated, as both beneficial and deleterious results have been reported
depending on the type of T-helper (Th) immune response set in motion after
the activation of lymphocytes.<sup><xref rid="bibr81-1756286418789854" ref-type="bibr">81</xref><xref rid="bibr82-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr83-1756286418789854" ref-type="bibr">83</xref></sup> Both transient
(mechanical) and permanent experimental models of stroke have shown that
lymphocyte infiltration into the ischemic tissue comes later after stroke
onset (starting at 3 days).<sup><xref rid="bibr14-1756286418789854" ref-type="bibr">14</xref>,<xref rid="bibr16-1756286418789854" ref-type="bibr">16</xref></sup> Postmortem human
samples have shown that lymphocyte infiltration into the ischemic area occur
from day 3 and can be present up to 53 years after stroke.<sup><xref rid="bibr15-1756286418789854" ref-type="bibr">15</xref></sup></p><p>The choroid plexuses (CP) have recently been proposed as the preferential
route for lymphocyte infiltration into the lesion site after experimental
stroke. Indeed, CP infarction reduces lymphocyte infiltration after stroke
onset; however, the ischemic volume is not modified in these mice, even if
lymphocyte infiltration is actually reduced.<sup><xref rid="bibr84-1756286418789854" ref-type="bibr">84</xref></sup> These intriguing results raise important questions about the role of
lymphocytes on the development of the ischemic lesion.</p></sec><sec id="section18-1756286418789854"><title>Therapeutic strategies targeting lymphocytes</title><p>Therapeutic strategies targeting lymphocytes would be desirable because they
focus the delayed phase of the injury and thus could have a particularly
wide therapeutic window. Several preclinical studies have shown that
pro-inflammatory lymphocytes, such as TH1, TH17, and &#x003b3;&#x003b4; T cells worsen
stroke outcome, and that blocking of their brain invasion is
neuroprotective.<sup><xref rid="bibr85-1756286418789854" ref-type="bibr">85</xref><xref rid="bibr86-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr87-1756286418789854" ref-type="bibr">87</xref></sup></p><p>Contrary to pro-inflammatory lymphocytes, regulatory T cells (Treg) and B
cells have been characterized as anti-inflammatory and as disease-limiting
protective cells. Targeting Tregs as the endogenous orchestrators of the
postischemic immune response has been proposed as a more effective therapy
than blocking only a particular inflammatory pathway.<sup><xref rid="bibr5-1756286418789854" ref-type="bibr">5</xref>,<xref rid="bibr13-1756286418789854" ref-type="bibr">13</xref></sup>
However, because of the complex function of regulatory cells in immune
homeostasis and disease, as well as partially divergent findings using
different stroke models, the pathophysiologic function of regulatory
lymphocytes in stroke remains uncertain. As an example, among nine studies
using Treg-depletion paradigms, three of the studies revealed an increase in
infarct volume<sup><xref rid="bibr88-1756286418789854" ref-type="bibr">88</xref><xref rid="bibr89-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr90-1756286418789854" ref-type="bibr">90</xref></sup> whereas five studies did not detect any effect on
stroke outcome<sup><xref rid="bibr88-1756286418789854" ref-type="bibr">88</xref>,<xref rid="bibr89-1756286418789854" ref-type="bibr">89</xref>,<xref rid="bibr91-1756286418789854" ref-type="bibr">91</xref><xref rid="bibr92-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr93-1756286418789854" ref-type="bibr">93</xref></sup> and one study even observed a reduction of infarct size
in Treg-deficient mice.<sup><xref rid="bibr94-1756286418789854" ref-type="bibr">94</xref></sup> To explain this, the experimental model used (permanent
<italic>versus</italic> transient mechanical) and more particularly, the
resulting volume of the ischemic lesion, has been proposed as a determinant
on the overall effect of Treg depletion that seems to provide a benefit only
on small lesion volumes provoked on the permanent stroke model.<sup><xref rid="bibr95-1756286418789854" ref-type="bibr">95</xref></sup></p><p>Another strategy for Treg modulation has been the administration of enhancers
of Treg function by adoptive cell transfer of purified Treg to wild-type
animals to increase circulating Treg numbers, or by the administration of a
CD28 superagonist (CD28SA), which provokes <italic>in vivo</italic>
expansion of Tregs and amplification of their suppressive function. However,
the obtained results are again controversial, with some studies describing
an improvement of stroke outcome<sup><xref rid="bibr96-1756286418789854" ref-type="bibr">96</xref></sup> and other studies describing an increase of ischemic volume.<sup><xref rid="bibr97-1756286418789854" ref-type="bibr">97</xref></sup> Once again, it has been proposed that stroke severity might predict
the net biological effect of Tregs.<sup><xref rid="bibr95-1756286418789854" ref-type="bibr">95</xref></sup></p><p>It has been proposed that Tregs have a deleterious role on ischemic stroke
not related to their established immunoregulatory characteristics but to a
specific effect on microvascular thrombus formation in a model of transient
mechanical occlusion.<sup><xref rid="bibr94-1756286418789854" ref-type="bibr">94</xref></sup> Secondary microthrombosis arises within minutes after reperfusion in
transient mechanical models of stroke once the occluding filament has been
removed. It provokes delayed cerebral blood flow (CBF) reduction, secondary
ischemia and lesion growth, which is responsible for ~70% of the final
ischemic lesion size.<sup><xref rid="bibr98-1756286418789854" ref-type="bibr">98</xref></sup> However, clinical studies have shown that secondary ischemia and
lesion growth are modest or nonexistent after reperfusion in selected
patients,<sup><xref rid="bibr2-1756286418789854" ref-type="bibr">2</xref>,<xref rid="bibr17-1756286418789854" ref-type="bibr">17</xref>,<xref rid="bibr99-1756286418789854" ref-type="bibr">99</xref>,<xref rid="bibr100-1756286418789854" ref-type="bibr">100</xref></sup> and concerns have been raised about the clinical
relevance of transient mechanical vascular occlusion stroke models.<sup><xref rid="bibr101-1756286418789854" ref-type="bibr">101</xref></sup> For these reasons, it would be interesting to test the role of Tregs
in nonmechanical models of ischemic stroke, where secondary microthrombosis
is absent.<sup><xref rid="bibr102-1756286418789854" ref-type="bibr">102</xref></sup></p><p>To increase the complexity of this question, fingolimod (FTY720), an
immunomodulatory drug currently approved by the US Food and Drug
Administration for the treatment of multiple sclerosis that inhibits
lymphocyte circulation and brain immigration, has been tested in models of
permanent and transient mechanical ischemia. As in the case of the
aforementioned CP infarction,<sup><xref rid="bibr84-1756286418789854" ref-type="bibr">84</xref></sup> although a reduction of lymphocyte brain invasion was detected using
fingolimod, no effect was observed on infarct volumes and behavioral
dysfunction in any of the models. This lack of neuroprotection despite
effective lymphopenia was attributed to a divergent impact of fingolimod on
cytokine expression and possible activation of innate immune cells after
brain ischemia.<sup><xref rid="bibr86-1756286418789854" ref-type="bibr">86</xref></sup> A phase II clinical trial using fingolimod (administered within 6 h
after the onset of symptoms) combined with alteplase and mechanical
thrombectomy on ischemic stroke (FAMTAIS) is ongoing.<sup><xref rid="bibr103-1756286418789854" ref-type="bibr">103</xref></sup></p><p>Two clinical pilot studies have tested fingolimod, alone and later than 4.5 h
after stroke onset for 3 days,<sup><xref rid="bibr104-1756286418789854" ref-type="bibr">104</xref></sup> or in combination with tPA (thus before 4.5 h after stroke onset) for
3 days.<sup><xref rid="bibr105-1756286418789854" ref-type="bibr">105</xref></sup> These two studies have shown a beneficial effect of the oral
administration of fingolimod within 72 h of stroke onset, especially when
combined with tPA, where patients who received the combination exhibited
smaller lesion volumes, less hemorrhage, and a better recovery at day
90.</p></sec><sec id="section19-1756286418789854"><title>Therapeutic strategies targeting global leukocyte infiltration</title><p>The transendothelial migration of leukocytes through the interaction between
the molecules VLA-4 (leukocyte very late antigen-4) (present at the surface
of neutrophils, monocytes, and T and B lymphocytes among other blood cell
types) and VCAM-1 (vascular cell adhesion molecule-1) has been targeted in
several studies. Antibodies against the alpha chain of VLA-4 (anti-CD49d
antibodies) have shown efficacy in several models of autoimmune diseases,
and the humanized antibody natalizumab is currently one of the most
effective therapies for patients with multiple sclerosis.<sup><xref rid="bibr106-1756286418789854" ref-type="bibr">106</xref></sup> However, preclinical data have shown conflicting results from four
positive and one inconclusive studies on the use of anti-CD49d antibodies on
ischemic stroke.<sup><xref rid="bibr86-1756286418789854" ref-type="bibr">86</xref>,<xref rid="bibr107-1756286418789854" ref-type="bibr">107</xref><xref rid="bibr108-1756286418789854" ref-type="bibr"/><xref rid="bibr109-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr110-1756286418789854" ref-type="bibr">110</xref></sup>
Recently, a preclinical randomized controlled multicenter trial highlighted
the importance of testing new therapies in different experimental stroke
models (discussed further on), since the administration of CD49d-antibodies
reduced both leukocyte invasion and infarct volume after the permanent
distal occlusion of the MCA (which causes a small cortical infarction),
whereas it did not reduce leukocyte invasion or infarct volume after
transient proximal mechanical occlusion of the MCA (which induces large lesions).<sup><xref rid="bibr111-1756286418789854" ref-type="bibr">111</xref></sup> These results could suggest that the benefits of immune-targeted
therapies may be dependent on infarct localization and severity.</p><p>The recently published results of the administration of one dose of
natalizumab in patients with acute ischemic stroke (ACTION trial) have shown
that natalizumab administered up to 9 h after stroke onset did not reduce
infarct growth (primary endpoint of the study), but more patients in the
natalizumab group than in the placebo group had mRS scores of 0 or 1 at day
30, although this beneficial effect disappeared 90 days after stroke.<sup><xref rid="bibr112-1756286418789854" ref-type="bibr">112</xref></sup> These results reinforce the need of new studies to understand (a) how
natalizumab exerts a positive effect on functional outcome without reducing
the infarct volume at 30 days, and (b) why this beneficial effect on
functional outcome is lost at 90 days. Additionally, the ACTION II trial has
been recently completed. Its primary objective was to assess the effects of
natalizumab on functional independence and activities of daily living.<sup><xref rid="bibr113-1756286418789854" ref-type="bibr">113</xref></sup> Results have not been published yet.</p></sec></sec></sec><sec id="section20-1756286418789854"><title>Immunomodulating therapies in stroke: a gap between our expectations and
reality</title><p>The reasons for the failure of immunomodulatory therapies in clinical trials are
multifactorial. As discussed, one of the main issues of the bench-to-bed translation
of immunomodulatory therapies for stroke is the huge gap between human
pathophysiology and the stroke models that have mainly been used to study stroke
immunology. In experimental stroke models, preclinical stroke research nowadays
disposes of a wide range of experimental models including permanent and transient
arterial occlusions. In addition to this, the origin of the occlusion may also vary
from a transient mechanical occlusion to real blood clots located in the lumen of
the artery. In the case of clot-induced stroke models, researchers can even adopt
different strategies to determine the nature of clots (fibrin-rich or platelet-rich)
and, consequently, clot susceptibility to thrombolytic agents<sup><xref rid="bibr114-1756286418789854" ref-type="bibr">114</xref><xref rid="bibr115-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr116-1756286418789854" ref-type="bibr">116</xref></sup> to mimic the heterogeneity
of human thrombi subtypes. It is important to note that despite the variety of
available stroke models, the vast majority of preclinical data on transient models
of ischemic stroke has been obtained on mechanical occlusion models that provoke
thromboinflammation and secondary microthrombosis. This secondary microthrombosis is
a major pathophysiologic mechanism leading to brain damage which does not occur in
other models based on clot-induced ischemic stroke like the thrombin-induced stroke
model.<sup><xref rid="bibr102-1756286418789854" ref-type="bibr">102</xref>,<xref rid="bibr116-1756286418789854" ref-type="bibr">116</xref></sup> As in the aforementioned case of Treg-targeted drugs,
immunomodulatory agents that have clearly shown beneficial effects on mechanical
occlusion models of stroke could actually be targeting thromboinflammation and
secondary microthrombosis. Since it is unclear whether thromboinflammation is a
universal pathophysiological mechanism of human stroke, immunomodulatory drugs
deserve to be evaluated or re-evaluated in experimental stroke models not inducing
secondary thromboinflammation before trying to apply them in clinical practice.</p><p>Other reasons for the failure in the translation of immunomodulatory therapies from
bench to bedside may include poorly designed preclinical and clinical studies, and
underpowered clinical trials with overambitious and pathophysiologically irrelevant
therapeutic windows.<sup><xref rid="bibr117-1756286418789854" ref-type="bibr">117</xref>,<xref rid="bibr118-1756286418789854" ref-type="bibr">118</xref></sup> In addition, a biased selection of substances for clinical
testing may partially explain the slow progress in developing treatments.<sup><xref rid="bibr118-1756286418789854" ref-type="bibr">118</xref></sup></p><p>It is also possible that the positive results seen with immunomodulatory drugs in
experimental studies are not transposable to the complexity and the variability of
the immunologic response in human stroke, which may depend on different parameters
including prestroke status of the patient and the natural history of the
disease.<sup><xref rid="bibr63-1756286418789854" ref-type="bibr">63</xref>,<xref rid="bibr93-1756286418789854" ref-type="bibr">93</xref></sup> In most animal studies, complete occlusion is induced and is
either maintained or followed by complete reperfusion. In human stroke, however,
only a few patients are likely to experience both complete occlusion and complete
reperfusion (excepting thrombectomized patients). The unlimited variety of outcomes
seen in stroke patients suggests that stroke itself, as well as the body&#x02019;s response
to ischemic stroke represents a seamless continuum of exigencies rather than the
definitive scenario employed in animal studies.<sup><xref rid="bibr68-1756286418789854" ref-type="bibr">68</xref></sup> In addition, stroke risk factors such as diet, smoking, aging,
atherosclerosis, hypertension, alcohol consumption and stress cannot be replicated
well in the laboratory; actually, most of the preclinical studies are performed in
healthy mice. Moreover, although stroke remains the third cause of death in women,<sup><xref rid="bibr119-1756286418789854" ref-type="bibr">119</xref></sup> most of the preclinical studies are performed on male animals. Inflammatory
cells such as microglia, dendritic cells, neutrophils and lymphocytes show
variations between sex, and so may play different roles in the pathophysiology of
stroke.<sup><xref rid="bibr120-1756286418789854" ref-type="bibr">120</xref><xref rid="bibr121-1756286418789854" ref-type="bibr"/><xref rid="bibr122-1756286418789854" ref-type="bibr"/>&#x02013;<xref rid="bibr123-1756286418789854" ref-type="bibr">123</xref></sup></p><p>The failure of immunomodulatory drugs clinically tested on stroke to date may also
indicate that the inflammatory response after stroke is an important aspect of the
regenerative process triggered after stroke and only becomes detrimental when
exaggerated, perhaps in relation to the severity of ischemic injury (as shown in
preclinical stroke models) or to concomitant disease states or risk factors.
However, many of the preclinical studies examining immunomodulation were targeted at
the acute phase, not during the phases where recovery is expected to occur. Thus,
this hypothesis needs to be addressed in future studies.</p><p>Another important element to be considered when testing immunomodulatory drugs for
stroke is that postischemic systemic immunomodulation and infectious complications
are some of the main comorbidities after stroke. In experimental models, the
systemic immune responses differ substantially among stroke models and infarct
volume.<sup><xref rid="bibr89-1756286418789854" ref-type="bibr">89</xref>,<xref rid="bibr124-1756286418789854" ref-type="bibr">124</xref></sup> Translational studies of immunomodulatory therapies for stroke
must account for this heterogeneity, especially in the case of drugs with long-term
effects such as natalizumab, that blocks the &#x003b1;-4 integrin for at least 4 weeks.<sup><xref rid="bibr125-1756286418789854" ref-type="bibr">125</xref></sup></p></sec><sec sec-type="conclusions" id="section21-1756286418789854"><title>Conclusion</title><p>Factors contributing to the failure in the translation of therapies targeting
stroke-induced immune responses to clinical practice include nonmodifiable factors
(differences in the cerebrovascular system in humans and rodents, variability in the
immune response in patients depending on their prestroke inflammatory status, which
is extremely difficult to mimic in animal models of stroke&#x02026;) that need to be
considered when interpreting results. However, most of these factors are modifiable
and include, among others, the use of clinically relevant stroke models and
therapeutic time windows, the comparison of a same molecule in different stroke
models, the improvement in the experimental designs and the inclusion of females and
comorbidities in preclinical studies.</p><p>Now that we are in the age of acute revascularization, one might wonder if we can do
better than thrombectomy for patients with penumbra. If the answer is &#x02018;no&#x02019; then
there is probably no need for immunomodulatory treatments for these patients. If the
answer is &#x02018;yes,&#x02019; and also for all the other patients, immunomodulation will retain
therapeutic interest. Preclinical studies should be conceived according to the
targeted stroke subpopulation. In any case, a strictly linear bench-to-bedside
paradigm is probably not optimal for translating basic scientific findings into
clinically effective stroke therapies, and a bedside-back-to-bench paradigm will
help in this translation.</p><p>In spite of the limitations of experimental stroke models, our knowledge about the
inflammatory responses triggered after stroke onset exponentially increases thanks
to preclinical and clinical studies, and gives rise to novel therapeutic targets and
improved strategies, with the hope of ameliorating stroke outcome in patients.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This research received no specific grant from any funding agency in the public,
commercial, or not-for-profit sectors.</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest statement:</bold> The authors declare that there is no conflict of interest.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Marina Rubio <inline-graphic xlink:href="10.1177_1756286418789854-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-6120-4053">https://orcid.org/0000-0002-6120-4053</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1756286418789854"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jovin</surname><given-names>TG</given-names></name><name><surname>Chamorro</surname><given-names>A</given-names></name><name><surname>Cobo</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Thrombectomy within 8 hours after symptom onset
in ischemic stroke</article-title>. <source>N Engl J Med</source>
<year>2015</year>; <volume>372</volume>:
<fpage>2296</fpage>&#x02013;<lpage>2306</lpage>.<pub-id pub-id-type="pmid">25882510</pub-id></mixed-citation></ref><ref id="bibr2-1756286418789854"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nogueira</surname><given-names>RG</given-names></name><name><surname>Jadhav</surname><given-names>AP</given-names></name><name><surname>Haussen</surname><given-names>DC</given-names></name><etal>et al</etal></person-group>
<article-title>Thrombectomy 6 to 24 hours after stroke with a
mismatch between deficit and infarct</article-title>. <source>N Engl J
Med</source>
<year>2018</year>; <volume>378</volume>:
<fpage>11</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">29129157</pub-id></mixed-citation></ref><ref id="bibr3-1756286418789854"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Albers</surname><given-names>GW</given-names></name><name><surname>Marks</surname><given-names>MP</given-names></name><name><surname>Kemp</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Thrombectomy for stroke at 6 to 16 hours with
selection by perfusion imaging</article-title>. <source>N Engl J
Med</source>
<year>2018</year>; <volume>378</volume>:
<fpage>708</fpage>&#x02013;<lpage>718</lpage>.<pub-id pub-id-type="pmid">29364767</pub-id></mixed-citation></ref><ref id="bibr4-1756286418789854"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fagan</surname><given-names>SC</given-names></name><name><surname>Cronic</surname><given-names>LE</given-names></name><name><surname>Hess</surname><given-names>DC.</given-names></name></person-group>
<article-title>Minocycline development for acute ischemic
stroke</article-title>. <source>Transl Stroke Res</source>. <year>2011</year>;
<volume>2</volume>: <fpage>202</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">21909339</pub-id></mixed-citation></ref><ref id="bibr5-1756286418789854"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Anrather</surname><given-names>J.</given-names></name></person-group>
<article-title>The immunology of stroke: from mechanisms to
translation</article-title>. <source>Nat Med</source>
<year>2011</year>; <volume>17</volume>:
<fpage>796</fpage>&#x02013;<lpage>808</lpage>.<pub-id pub-id-type="pmid">21738161</pub-id></mixed-citation></ref><ref id="bibr6-1756286418789854"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>DW.</given-names></name></person-group>
<article-title>Glutamate neurotoxicity in cortical cell culture is calcium
dependent</article-title>. <source>Neurosci Lett</source>
<year>1985</year>; <volume>58</volume>:
<fpage>293</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">2413399</pub-id></mixed-citation></ref><ref id="bibr7-1756286418789854"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koistinaho</surname><given-names>M</given-names></name><name><surname>Koistinaho</surname><given-names>J.</given-names></name></person-group>
<article-title>Interactions between Alzheimer&#x02019;s disease and cerebral
ischemia&#x02014;focus on inflammation</article-title>. <source>Brain Res Brain Res
Rev</source>
<year>2005</year>; <volume>48</volume>:
<fpage>240</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">15850663</pub-id></mixed-citation></ref><ref id="bibr8-1756286418789854"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyaji</surname><given-names>Y</given-names></name><name><surname>Yoshimura</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of edaravone on favorable outcome in
patients with acute cerebral large vessel occlusion: subanalysis of
RESCUE-Japan Registry</article-title>. <source>Neurol Med Chir
(Tokyo)</source>
<year>2015</year>; <volume>55</volume>:
<fpage>241</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">25739433</pub-id></mixed-citation></ref><ref id="bibr9-1756286418789854"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perego</surname><given-names>C</given-names></name><name><surname>Fumagalli</surname><given-names>S</given-names></name><name><surname>De Simoni</surname><given-names>M-G.</given-names></name></person-group>
<article-title>Temporal pattern of expression and colocalization of
microglia/macrophage phenotype markers following brain ischemic injury in
mice</article-title>. <source>J Neuroinflammation</source>
<year>2011</year>; <volume>8</volume>: <fpage>174</fpage>.<pub-id pub-id-type="pmid">22152337</pub-id></mixed-citation></ref><ref id="bibr10-1756286418789854"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Upadhyay</surname><given-names>UM</given-names></name><name><surname>Tamargo</surname><given-names>RJ.</given-names></name></person-group>
<article-title>Inflammation in stroke and focal cerebral
ischemia</article-title>. <source>Surg Neurol</source>
<year>2006</year>; <volume>66</volume>:
<fpage>232</fpage>&#x02013;<lpage>245</lpage>.<pub-id pub-id-type="pmid">16935624</pub-id></mixed-citation></ref><ref id="bibr11-1756286418789854"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>WA.</given-names></name></person-group>
<article-title>Leukocyte-endothelial cell interactions in the inflammatory
response</article-title>. <source>Lab Investig J Tech Methods
Pathol</source>
<year>2002</year>; <volume>82</volume>:
<fpage>521</fpage>&#x02013;<lpage>533</lpage>.</mixed-citation></ref><ref id="bibr12-1756286418789854"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engelhardt</surname><given-names>B</given-names></name><name><surname>Ransohoff</surname><given-names>RM.</given-names></name></person-group>
<article-title>The ins and outs of T-lymphocyte trafficking to the CNS:
anatomical sites and molecular mechanisms</article-title>. <source>Trends
Immunol</source>
<year>2005</year>; <volume>26</volume>:
<fpage>485</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">16039904</pub-id></mixed-citation></ref><ref id="bibr13-1756286418789854"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eltzschig</surname><given-names>HK</given-names></name><name><surname>Eckle</surname><given-names>T.</given-names></name></person-group>
<article-title>Ischemia and reperfusion&#x02014;from mechanism to
translation</article-title>. <source>Nat Med</source>
<year>2011</year>; <volume>17</volume>:
<fpage>1391</fpage>&#x02013;<lpage>1401</lpage>.<pub-id pub-id-type="pmid">22064429</pub-id></mixed-citation></ref><ref id="bibr14-1756286418789854"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gelderblom</surname><given-names>M</given-names></name><name><surname>Leypoldt</surname><given-names>F</given-names></name><name><surname>Steinbach</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Temporal and spatial dynamics of cerebral immune
cell accumulation in stroke</article-title>. <source>Stroke</source>
<year>2009</year>; <volume>40</volume>:
<fpage>1849</fpage>&#x02013;<lpage>1857</lpage>.<pub-id pub-id-type="pmid">19265055</pub-id></mixed-citation></ref><ref id="bibr15-1756286418789854"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mena</surname><given-names>H</given-names></name><name><surname>Cadavid</surname><given-names>D</given-names></name><name><surname>Rushing</surname><given-names>EJ.</given-names></name></person-group>
<article-title>Human cerebral infarct: a proposed histopathologic classification
based on 137 cases</article-title>. <source>Acta Neuropathol (Berl)</source>
<year>2004</year>; <volume>108</volume>:
<fpage>524</fpage>&#x02013;<lpage>530</lpage>.<pub-id pub-id-type="pmid">15517310</pub-id></mixed-citation></ref><ref id="bibr16-1756286418789854"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Liesz</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Postischemic brain infiltration of leukocyte
subpopulations differs among murine permanent and transient focal cerebral
ischemia models: infiltration differs among cerebral
ischemia</article-title>. <source>Brain Pathol</source>
<year>2013</year>; <volume>23</volume>:
<fpage>34</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22775530</pub-id></mixed-citation></ref><ref id="bibr17-1756286418789854"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lansberg</surname><given-names>MG</given-names></name><name><surname>Straka</surname><given-names>M</given-names></name><name><surname>Kemp</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>MRI profile and response to endovascular
reperfusion after stroke (DEFUSE 2): a prospective cohort
study</article-title>. <source>Lancet Neurol</source>
<year>2012</year>; <volume>11</volume>:
<fpage>860</fpage>&#x02013;<lpage>867</lpage>.<pub-id pub-id-type="pmid">22954705</pub-id></mixed-citation></ref><ref id="bibr18-1756286418789854"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kyritsis</surname><given-names>N</given-names></name><name><surname>Kizil</surname><given-names>C</given-names></name><name><surname>Zocher</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Acute inflammation initiates the regenerative
response in the adult zebrafish brain</article-title>.
<source>Science</source>
<year>2012</year>; <volume>338</volume>:
<fpage>1353</fpage>&#x02013;<lpage>1356</lpage>.<pub-id pub-id-type="pmid">23138980</pub-id></mixed-citation></ref><ref id="bibr19-1756286418789854"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macrez</surname><given-names>R</given-names></name><name><surname>Ali</surname><given-names>C</given-names></name><name><surname>Toutirais</surname><given-names>O</given-names></name><etal>et al</etal></person-group>
<article-title>Stroke and the immune system: from
pathophysiology to new therapeutic strategies</article-title>.
<source>Lancet Neurol</source>
<year>2011</year>; <volume>10</volume>:
<fpage>471</fpage>&#x02013;<lpage>480</lpage>.<pub-id pub-id-type="pmid">21511199</pub-id></mixed-citation></ref><ref id="bibr20-1756286418789854"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tobin</surname><given-names>MK</given-names></name><name><surname>Bonds</surname><given-names>JA</given-names></name><name><surname>Minshall</surname><given-names>RD</given-names></name><etal>et al</etal></person-group>
<article-title>Neurogenesis and inflammation after ischemic
stroke: what is known and where we go from here</article-title>. <source>J
Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab</source>
<year>2014</year>; <volume>34</volume>:
<fpage>1573</fpage>&#x02013;<lpage>1584</lpage>.</mixed-citation></ref><ref id="bibr21-1756286418789854"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peruzzotti-Jametti</surname><given-names>L</given-names></name><name><surname>Doneg&#x000e1;</surname><given-names>M</given-names></name><name><surname>Giusto</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>The role of the immune system in central nervous
system plasticity after acute injury</article-title>.
<source>Neuroscience</source>
<year>2014</year>; <volume>283</volume>:
<fpage>210</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">24785677</pub-id></mixed-citation></ref><ref id="bibr22-1756286418789854"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Kipnis</surname><given-names>J</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>How do immune cells support and shape the brain
in health, disease, and aging?</article-title>
<source>J Neurosci Off J Soc Neurosci</source>
<year>2013</year>; <volume>33</volume>:
<fpage>17587</fpage>&#x02013;<lpage>17596</lpage>.</mixed-citation></ref><ref id="bibr23-1756286418789854"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nowicka</surname><given-names>D</given-names></name><name><surname>Rogozinska</surname><given-names>K</given-names></name><name><surname>Aleksy</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Spatiotemporal dynamics of astroglial and
microglial responses after photothrombotic stroke in the rat
brain</article-title>. <source>Acta Neurobiol Exp (Warsz)</source>
<year>2008</year>; <volume>68</volume>:
<fpage>155</fpage>&#x02013;<lpage>168</lpage>.<pub-id pub-id-type="pmid">18511952</pub-id></mixed-citation></ref><ref id="bibr24-1756286418789854"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lively</surname><given-names>S</given-names></name><name><surname>Moxon-Emre</surname><given-names>I</given-names></name><name><surname>Schlichter</surname><given-names>LC.</given-names></name></person-group>
<article-title>SC1/hevin and reactive gliosis after transient ischemic stroke in
young and aged rats</article-title>. <source>J Neuropathol Exp
Neurol</source>
<year>2011</year>; <volume>70</volume>:
<fpage>913</fpage>&#x02013;<lpage>929</lpage>.<pub-id pub-id-type="pmid">21937915</pub-id></mixed-citation></ref><ref id="bibr25-1756286418789854"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morioka</surname><given-names>T</given-names></name><name><surname>Kalehua</surname><given-names>AN</given-names></name><name><surname>Streit</surname><given-names>WJ.</given-names></name></person-group>
<article-title>Characterization of microglial reaction after middle cerebral
artery occlusion in rat brain</article-title>. <source>J Comp
Neurol</source>
<year>1993</year>; <volume>327</volume>:
<fpage>123</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">8432904</pub-id></mixed-citation></ref><ref id="bibr26-1756286418789854"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z-B</given-names></name><name><surname>Zhuge</surname><given-names>Q</given-names></name><etal>et al</etal></person-group>
<article-title>Glial scar formation occurs in the human brain
after ischemic stroke</article-title>. <source>Int J Med Sci</source>
<year>2014</year>; <volume>11</volume>:
<fpage>344</fpage>&#x02013;<lpage>348</lpage>.<pub-id pub-id-type="pmid">24578611</pub-id></mixed-citation></ref><ref id="bibr27-1756286418789854"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krieger</surname><given-names>DW</given-names></name><name><surname>Georgia</surname><given-names>MAD</given-names></name><name><surname>Abou-Chebl</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Cooling for Acute Ischemic Brain Damage (COOL
AID): an open pilot study of induced hypothermia in acute ischemic
stroke</article-title>. <source>Stroke</source>
<year>2001</year>; <volume>32</volume>:
<fpage>1847</fpage>&#x02013;<lpage>1854</lpage>.<pub-id pub-id-type="pmid">11486115</pub-id></mixed-citation></ref><ref id="bibr28-1756286418789854"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Georgia</surname><given-names>MA</given-names></name><name><surname>Krieger</surname><given-names>DW</given-names></name><name><surname>Abou-Chebl</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Cooling for Acute Ischemic Brain Damage (COOL
AID): a feasibility trial of endovascular cooling</article-title>.
<source>Neurology</source>
<year>2004</year>; <volume>63</volume>:
<fpage>312</fpage>&#x02013;<lpage>317</lpage>.<pub-id pub-id-type="pmid">15277626</pub-id></mixed-citation></ref><ref id="bibr29-1756286418789854"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyden</surname><given-names>PD</given-names></name><name><surname>Allgren</surname><given-names>RL</given-names></name><name><surname>Ng</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Intravascular Cooling in the Treatment of Stroke
(ICTuS): early clinical experience</article-title>. <source>J Stroke
Cerebrovasc Dis Off J Natl Stroke Assoc</source>
<year>2005</year>; <volume>14</volume>:
<fpage>107</fpage>&#x02013;<lpage>114</lpage>.</mixed-citation></ref><ref id="bibr30-1756286418789854"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hemmen</surname><given-names>TM</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Guluma</surname><given-names>KZ</given-names></name><etal>et al</etal></person-group>
<article-title>Intravenous thrombolysis plus hypothermia for
acute treatment of ischemic stroke (ICTuS-L): final results</article-title>.
<source>Stroke</source>
<year>2010</year>; <volume>41</volume>:
<fpage>2265</fpage>&#x02013;<lpage>2270</lpage>.<pub-id pub-id-type="pmid">20724711</pub-id></mixed-citation></ref><ref id="bibr31-1756286418789854"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyden</surname><given-names>P</given-names></name><name><surname>Hemmen</surname><given-names>T</given-names></name><name><surname>Grotta</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Results of the ICTuS 2 trial (Intravascular
Cooling in the Treatment of Stroke 2)</article-title>.
<source>Stroke</source>
<year>2016</year>; <volume>47</volume>:
<fpage>2888</fpage>&#x02013;<lpage>2895</lpage>.<pub-id pub-id-type="pmid">27834742</pub-id></mixed-citation></ref><ref id="bibr32-1756286418789854"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Worp</surname><given-names>HB1</given-names></name><name><surname>Macleod</surname><given-names>MR</given-names></name><name><surname>Bath</surname><given-names>PM</given-names></name><etal>et al</etal></person-group>
<article-title>Trial of therapeutic cooling in patients with
acute ischaemic stroke</article-title>, <source>Int J Stroke</source>
<year>2014</year>; <volume>9</volume>(<issue>5</issue>):
<fpage>642</fpage>&#x02013;<lpage>645</lpage>. doi: 10.1111/ijs.12294. <ext-link ext-link-type="uri" xlink:href="https://www.eurohyp1.eu/">https://www.eurohyp1.eu/</ext-link> (<comment>accessed 15 May
2018</comment>).<pub-id pub-id-type="pmid">24828363</pub-id></mixed-citation></ref><ref id="bibr33-1756286418789854"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lawson</surname><given-names>LJ</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Gordon</surname><given-names>S.</given-names></name></person-group>
<article-title>Turnover of resident microglia in the normal adult mouse
brain</article-title>. <source>Neuroscience</source>
<year>1992</year>; <volume>48</volume>:
<fpage>405</fpage>&#x02013;<lpage>415</lpage>.<pub-id pub-id-type="pmid">1603325</pub-id></mixed-citation></ref><ref id="bibr34-1756286418789854"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kettenmann</surname><given-names>H</given-names></name><name><surname>Hanisch</surname><given-names>U-K</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Physiology of microglia</article-title>.
<source>Physiol Rev</source>
<year>2011</year>; <volume>91</volume>:
<fpage>461</fpage>&#x02013;<lpage>553</lpage>.<pub-id pub-id-type="pmid">21527731</pub-id></mixed-citation></ref><ref id="bibr35-1756286418789854"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>GY</given-names></name><name><surname>Nu&#x000f1;ez</surname><given-names>G.</given-names></name></person-group>
<article-title>Sterile inflammation: sensing and reacting to
damage</article-title>. <source>Nat Rev Immunol</source>
<year>2010</year>; <volume>10</volume>:
<fpage>826</fpage>&#x02013;<lpage>837</lpage>.<pub-id pub-id-type="pmid">21088683</pub-id></mixed-citation></ref><ref id="bibr36-1756286418789854"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez-Fernandez</surname><given-names>S</given-names></name><name><surname>Almeida</surname><given-names>A</given-names></name><name><surname>Bola&#x000f1;os</surname><given-names>JP.</given-names></name></person-group>
<article-title>Antioxidant and bioenergetic coupling between neurons and
astrocytes</article-title>. <source>Biochem J</source>
<year>2012</year>; <volume>443</volume>:
<fpage>3</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">22417747</pub-id></mixed-citation></ref><ref id="bibr37-1756286418789854"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez-Lizarbe</surname><given-names>S</given-names></name><name><surname>Pascual</surname><given-names>M</given-names></name><name><surname>Guerri</surname><given-names>C.</given-names></name></person-group>
<article-title>Critical role of TLR4 response in the activation of microglia
induced by ethanol</article-title>. <source>J Immunol</source>
<year>2009</year>; <volume>183</volume>:
<fpage>4733</fpage>&#x02013;<lpage>4744</lpage>.<pub-id pub-id-type="pmid">19752239</pub-id></mixed-citation></ref><ref id="bibr38-1756286418789854"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cardona</surname><given-names>AE</given-names></name><name><surname>Pioro</surname><given-names>EP</given-names></name><name><surname>Sasse</surname><given-names>ME</given-names></name><etal>et al</etal></person-group>
<article-title>Control of microglial neurotoxicity by the
fractalkine receptor</article-title>. <source>Nat Neurosci</source>
<year>2006</year>; <volume>9</volume>:
<fpage>917</fpage>&#x02013;<lpage>924</lpage>.<pub-id pub-id-type="pmid">16732273</pub-id></mixed-citation></ref><ref id="bibr39-1756286418789854"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banwell</surname><given-names>V</given-names></name><name><surname>Sena</surname><given-names>ES</given-names></name><name><surname>Macleod</surname><given-names>MR.</given-names></name></person-group>
<article-title>Systematic review and stratified meta-analysis of the efficacy of
interleukin-1 receptor antagonist in animal models of
stroke</article-title>. <source>J Stroke Cerebrovasc Dis Off J Natl Stroke
Assoc</source>
<year>2009</year>; <volume>18</volume>:
<fpage>269</fpage>&#x02013;<lpage>276</lpage>.</mixed-citation></ref><ref id="bibr40-1756286418789854"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emsley</surname><given-names>HCA</given-names></name><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Georgiou</surname><given-names>RF</given-names></name><etal>et al</etal></person-group>
<article-title>A randomised phase II study of interleukin-1
receptor antagonist in acute stroke patients</article-title>. <source>J
Neurol Neurosurg Psychiatry</source>
<year>2005</year>; <volume>76</volume>:
<fpage>1366</fpage>&#x02013;<lpage>1372</lpage>.<pub-id pub-id-type="pmid">16170078</pub-id></mixed-citation></ref><ref id="bibr41-1756286418789854"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Hulme</surname><given-names>S</given-names></name><name><surname>Vail</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>SCIL-STROKE (Subcutaneous Interleukin-1 Receptor
Antagonist in Ischemic Stroke): a randomized controlled phase 2
trial</article-title>. <source>Stroke</source>
<year>2018</year>; <volume>49</volume>:
<fpage>1210</fpage>&#x02013;<lpage>1216</lpage>.<pub-id pub-id-type="pmid">29567761</pub-id></mixed-citation></ref><ref id="bibr42-1756286418789854"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Szalay</surname><given-names>G</given-names></name><name><surname>Martinecz</surname><given-names>B</given-names></name><name><surname>L&#x000e9;n&#x000e1;rt</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Microglia protect against brain injury and their
selective elimination dysregulates neuronal network activity after
stroke</article-title>. <source>Nat Commun</source>
<year>2016</year>; <volume>7</volume>: <fpage>11499</fpage>.<pub-id pub-id-type="pmid">27139776</pub-id></mixed-citation></ref><ref id="bibr43-1756286418789854"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohler</surname><given-names>E</given-names></name><name><surname>Prentice</surname><given-names>DA</given-names></name><name><surname>Bates</surname><given-names>TR</given-names></name><etal>et al</etal></person-group>
<article-title>Intravenous minocycline in acute stroke: a
randomized, controlled pilot study and meta-analysis</article-title>.
<source>Stroke</source>
<year>2013</year>; <volume>44</volume>:
<fpage>2493</fpage>&#x02013;<lpage>2499</lpage>.<pub-id pub-id-type="pmid">23868273</pub-id></mixed-citation></ref><ref id="bibr44-1756286418789854"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lapchak</surname><given-names>PA</given-names></name><name><surname>Chapman</surname><given-names>DF</given-names></name><name><surname>Zivin</surname><given-names>JA.</given-names></name></person-group>
<article-title>Metalloproteinase inhibition reduces thrombolytic (tissue
plasminogen activator)-induced hemorrhage after thromboembolic
stroke</article-title>. <source>Stroke</source>
<year>2000</year>; <volume>31</volume>:
<fpage>3034</fpage>&#x02013;<lpage>3040</lpage>.<pub-id pub-id-type="pmid">11108768</pub-id></mixed-citation></ref><ref id="bibr45-1756286418789854"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>CZ</given-names></name><name><surname>Xue</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Matrix metalloproteinase-9 inhibition attenuates
vascular endothelial growth factor-induced intracerebral
hemorrhage</article-title>. <source>Stroke</source>
<year>2007</year>; <volume>38</volume>:
<fpage>2563</fpage>&#x02013;<lpage>2568</lpage>.<pub-id pub-id-type="pmid">17673717</pub-id></mixed-citation></ref><ref id="bibr46-1756286418789854"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Machado</surname><given-names>LS</given-names></name><name><surname>Sazonova</surname><given-names>IY</given-names></name><name><surname>Kozak</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Minocycline and tissue-type plasminogen
activator for stroke: assessment of interaction potential</article-title>.
<source>Stroke</source>
<year>2009</year>; <volume>40</volume>:
<fpage>3028</fpage>&#x02013;<lpage>3033</lpage>.<pub-id pub-id-type="pmid">19628804</pub-id></mixed-citation></ref><ref id="bibr47-1756286418789854"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsukawa</surname><given-names>N</given-names></name><name><surname>Yasuhara</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Therapeutic targets and limits of minocycline
neuroprotection in experimental ischemic stroke</article-title>. <source>BMC
Neurosci</source>
<year>2009</year>; <volume>10</volume>: <fpage>126</fpage>.<pub-id pub-id-type="pmid">19807907</pub-id></mixed-citation></ref><ref id="bibr48-1756286418789854"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>N</given-names></name><name><surname>Shimazawa</surname><given-names>M</given-names></name><name><surname>Yamashima</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Minocycline inhibits oxidative stress and
decreases in vitro and in vivo ischemic neuronal damage</article-title>.
<source>Brain Res</source>
<year>2005</year>; <volume>1044</volume>:
<fpage>8</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">15862784</pub-id></mixed-citation></ref><ref id="bibr49-1756286418789854"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murata</surname><given-names>Y</given-names></name><name><surname>Rosell</surname><given-names>A</given-names></name><name><surname>Scannevin</surname><given-names>RH</given-names></name><etal>et al</etal></person-group>
<article-title>Extension of the thrombolytic time window with
minocycline in experimental stroke</article-title>. <source>Stroke</source>
<year>2008</year>; <volume>39</volume>:
<fpage>3372</fpage>&#x02013;<lpage>3377</lpage>.<pub-id pub-id-type="pmid">18927459</pub-id></mixed-citation></ref><ref id="bibr50-1756286418789854"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Plane</surname><given-names>JM</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Pleasure</surname><given-names>DE</given-names></name><etal>et al</etal></person-group>
<article-title>Prospects for minocycline
neuroprotection</article-title>. <source>Arch Neurol</source>
<year>2010</year>; <volume>67</volume>:
<fpage>1442</fpage>&#x02013;<lpage>1448</lpage>.<pub-id pub-id-type="pmid">20697034</pub-id></mixed-citation></ref><ref id="bibr51-1756286418789854"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Henry</surname><given-names>S</given-names></name><name><surname>Del Bigio</surname><given-names>MR</given-names></name><etal>et al</etal></person-group>
<article-title>Intracerebral hemorrhage induces macrophage
activation and matrix metalloproteinases</article-title>. <source>Ann
Neurol</source>
<year>2003</year>; <volume>53</volume>:
<fpage>731</fpage>&#x02013;<lpage>742</lpage>.<pub-id pub-id-type="pmid">12783419</pub-id></mixed-citation></ref><ref id="bibr52-1756286418789854"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanchez Mejia</surname><given-names>RO</given-names></name><name><surname>Ona</surname><given-names>VO</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Minocycline reduces traumatic brain
injury-mediated caspase-1 activation, tissue damage, and neurological
dysfunction</article-title>. <source>Neurosurgery</source>
<year>2001</year>; <volume>48</volume>: <fpage>1393</fpage>&#x02013;<lpage>1399</lpage>;
discussion 1399&#x02013;1401.<pub-id pub-id-type="pmid">11383749</pub-id></mixed-citation></ref><ref id="bibr53-1756286418789854"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stirling</surname><given-names>DP</given-names></name><name><surname>Khodarahmi</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Minocycline treatment reduces delayed
oligodendrocyte death, attenuates axonal dieback, and improves functional
outcome after spinal cord injury</article-title>. <source>J Neurosci Off J
Soc Neurosci</source>
<year>2004</year>; <volume>24</volume>:
<fpage>2182</fpage>&#x02013;<lpage>2190</lpage>.</mixed-citation></ref><ref id="bibr54-1756286418789854"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teng</surname><given-names>YD</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Onario</surname><given-names>RC</given-names></name><etal>et al</etal></person-group>
<article-title>Minocycline inhibits contusion-triggered
mitochondrial cytochrome c release and mitigates functional deficits after
spinal cord injury</article-title>. <source>Proc Natl Acad Sci U S
A</source>
<year>2004</year>; <volume>101</volume>:
<fpage>3071</fpage>&#x02013;<lpage>3076</lpage>.<pub-id pub-id-type="pmid">14981254</pub-id></mixed-citation></ref><ref id="bibr55-1756286418789854"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>CX</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Noor</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Delayed minocycline but not delayed mild
hypothermia protects against embolic stroke</article-title>. <source>BMC
Neurol</source>
<year>2002</year>; <volume>2</volume>: <fpage>2</fpage>.<pub-id pub-id-type="pmid">11960560</pub-id></mixed-citation></ref><ref id="bibr56-1756286418789854"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wells</surname><given-names>JEA</given-names></name><name><surname>Hurlbert</surname><given-names>RJ</given-names></name><name><surname>Fehlings</surname><given-names>MG</given-names></name><etal>et al</etal></person-group>
<article-title>Neuroprotection by minocycline facilitates
significant recovery from spinal cord injury in mice</article-title>.
<source>Brain J Neurol</source>
<year>2003</year>; <volume>126</volume>(<issue>Pt 7</issue>):
<fpage>1628</fpage>&#x02013;<lpage>1637</lpage>.</mixed-citation></ref><ref id="bibr57-1756286418789854"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Fagan</surname><given-names>SC</given-names></name><name><surname>Waller</surname><given-names>JL</given-names></name><etal>et al</etal></person-group>
<article-title>Low dose intravenous minocycline is
neuroprotective after middle cerebral artery occlusion-reperfusion in
rats</article-title>. <source>BMC Neurol</source>
<year>2004</year>; <volume>4</volume>: <fpage>7</fpage>.<pub-id pub-id-type="pmid">15109399</pub-id></mixed-citation></ref><ref id="bibr58-1756286418789854"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yong</surname><given-names>VW</given-names></name><name><surname>Wells</surname><given-names>J</given-names></name><name><surname>Giuliani</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>The promise of minocycline in
neurology</article-title>. <source>Lancet Neurol</source>
<year>2004</year>; <volume>3</volume>:
<fpage>744</fpage>&#x02013;<lpage>751</lpage>.<pub-id pub-id-type="pmid">15556807</pub-id></mixed-citation></ref><ref id="bibr59-1756286418789854"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lampl</surname><given-names>Y</given-names></name><name><surname>Boaz</surname><given-names>M</given-names></name><name><surname>Gilad</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Minocycline treatment in acute stroke: an
open-label, evaluator-blinded study</article-title>.
<source>Neurology</source>
<year>2007</year>; <volume>69</volume>:
<fpage>1404</fpage>&#x02013;<lpage>1410</lpage>.<pub-id pub-id-type="pmid">17909152</pub-id></mixed-citation></ref><ref id="bibr60-1756286418789854"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Padma Srivastava</surname><given-names>MV</given-names></name><name><surname>Bhasin</surname><given-names>A</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Efficacy of minocycline in acute ischemic
stroke: a single-blinded, placebo-controlled trial</article-title>.
<source>Neurol India</source>
<year>2012</year>; <volume>60</volume>:
<fpage>23</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">22406775</pub-id></mixed-citation></ref><ref id="bibr61-1756286418789854"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>ST2/IL-33-dependent microglial response limits
acute ischemic brain injury</article-title>. <source>J Neurosci Off J Soc
Neurosci</source>
<year>2017</year>; <volume>37</volume>:
<fpage>4692</fpage>&#x02013;<lpage>4704</lpage>.</mixed-citation></ref><ref id="bibr62-1756286418789854"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Interleukin-4 is essential for
microglia/macrophage M2 polarization and long-term recovery after cerebral
ischemia</article-title>. <source>Stroke</source>
<year>2016</year>; <volume>47</volume>:
<fpage>498</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">26732561</pub-id></mixed-citation></ref><ref id="bibr63-1756286418789854"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gauberti</surname><given-names>M</given-names></name><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Marcos-Contreras</surname><given-names>OA</given-names></name><etal>et al</etal></person-group>
<article-title>Ultra-sensitive molecular MRI of vascular cell
adhesion molecule-1 reveals a dynamic inflammatory penumbra after
strokes</article-title>. <source>Stroke</source>
<year>2013</year>; <volume>44</volume>:
<fpage>1988</fpage>&#x02013;<lpage>1996</lpage>.<pub-id pub-id-type="pmid">23743972</pub-id></mixed-citation></ref><ref id="bibr64-1756286418789854"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Gauberti</surname><given-names>M</given-names></name><name><surname>Macrez</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Ultra-sensitive molecular MRI of cerebrovascular
cell activation enables early detection of chronic central nervous system
disorders</article-title>. <source>NeuroImage</source>
<year>2012</year>; <volume>63</volume>:
<fpage>760</fpage>&#x02013;<lpage>770</lpage>.<pub-id pub-id-type="pmid">22813950</pub-id></mixed-citation></ref><ref id="bibr65-1756286418789854"><label>65</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Granger</surname><given-names>DN</given-names></name><name><surname>Senchenkova</surname><given-names>E.</given-names></name></person-group>
<source>Inflammation and the microcirculation</source>. <publisher-loc>San
Rafael (CA)</publisher-loc>: <publisher-name>Morgan &#x00026; Claypool Life
Sciences</publisher-name>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK53373/">http://www.ncbi.nlm.nih.gov/books/NBK53373/</ext-link> (<year>2010</year>,
<comment>accessed 12 March 2018</comment>).</mixed-citation></ref><ref id="bibr66-1756286418789854"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gauberti</surname><given-names>M</given-names></name><name><surname>Fournier</surname><given-names>AP</given-names></name><name><surname>Docagne</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Molecular magnetic resonance imaging of
endothelial activation in the central nervous system</article-title>.
<source>Theranostics</source>
<year>2018</year>; <volume>8</volume>:
<fpage>1195</fpage>&#x02013;<lpage>1212</lpage>.<pub-id pub-id-type="pmid">29507614</pub-id></mixed-citation></ref><ref id="bibr67-1756286418789854"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bowes</surname><given-names>MP</given-names></name><name><surname>Rothlein</surname><given-names>R</given-names></name><name><surname>Fagan</surname><given-names>SC</given-names></name><etal>et al</etal></person-group>
<article-title>Monoclonal antibodies preventing leukocyte
activation reduce experimental neurologic injury and enhance efficacy of
thrombolytic therapy</article-title>. <source>Neurology</source>
<year>1995</year>; <volume>45</volume>:
<fpage>815</fpage>&#x02013;<lpage>819</lpage>.<pub-id pub-id-type="pmid">7723976</pub-id></mixed-citation></ref><ref id="bibr68-1756286418789854"><label>68</label><mixed-citation publication-type="journal">
<collab>Enlimomab Acute Stroke Trial Investigators</collab>. <article-title>Use
of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute
Stroke Trial</article-title>. <source>Neurology</source>
<year>2001</year>; <volume>57</volume>:
<fpage>1428</fpage>&#x02013;<lpage>1434</lpage>.<pub-id pub-id-type="pmid">11673584</pub-id></mixed-citation></ref><ref id="bibr69-1756286418789854"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeGraba</surname><given-names>TJ.</given-names></name></person-group>
<article-title>The role of inflammation after acute stroke: utility of pursuing
anti-adhesion molecule therapy</article-title>. <source>Neurology</source>
<year>1998</year>; <volume>51</volume>(<issue>3</issue>
<supplement>Suppl 3</supplement>):
<fpage>S62</fpage>&#x02013;<lpage>S68</lpage>.<pub-id pub-id-type="pmid">9744839</pub-id></mixed-citation></ref><ref id="bibr70-1756286418789854"><label>70</label><mixed-citation publication-type="gov">
<collab>Cayce Onks</collab>. <source>E-selectin nasal spray to prevent stroke
recurrence</source>. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00012454">https://clinicaltrials.gov/ct2/show/NCT00012454</ext-link>
(<comment>accessed 22 March 2018</comment>).</mixed-citation></ref><ref id="bibr71-1756286418789854"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bednar</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Humanized anti-L-selectin monoclonal antibody
DREC200 therapy in acute thromboembolic stroke</article-title>.
<source>Neurol Res</source>
<year>1998</year>; <volume>20</volume>:
<fpage>403</fpage>&#x02013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">9664585</pub-id></mixed-citation></ref><ref id="bibr72-1756286418789854"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nathan</surname><given-names>C.</given-names></name></person-group>
<article-title>Neutrophils and immunity: challenges and
opportunities</article-title>. <source>Nat Rev Immunol</source>
<year>2006</year>; <volume>6</volume>:
<fpage>173</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">16498448</pub-id></mixed-citation></ref><ref id="bibr73-1756286418789854"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Enzmann</surname><given-names>G</given-names></name><name><surname>Mysiorek</surname><given-names>C</given-names></name><name><surname>Gorina</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>The neurovascular unit as a selective barrier to
polymorphonuclear granulocyte (PMN) infiltration into the brain after
ischemic injury</article-title>. <source>Acta Neuropathol (Berl)</source>
<year>2013</year>; <volume>125</volume>:
<fpage>395</fpage>&#x02013;<lpage>412</lpage>.<pub-id pub-id-type="pmid">23269317</pub-id></mixed-citation></ref><ref id="bibr74-1756286418789854"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chu</surname><given-names>HX</given-names></name><name><surname>Kim</surname><given-names>HA</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Immune cell infiltration in malignant middle
cerebral artery infarction: comparison with transient cerebral
ischemia</article-title>. <source>J Cereb Blood Flow Metab Off J Int Soc
Cereb Blood Flow Metab</source>
<year>2014</year>; <volume>34</volume>:
<fpage>450</fpage>&#x02013;<lpage>459</lpage>.</mixed-citation></ref><ref id="bibr75-1756286418789854"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perez-de-Puig</surname><given-names>I</given-names></name><name><surname>Mir&#x000f3;-Mur</surname><given-names>F</given-names></name><name><surname>Ferrer-Ferrer</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Neutrophil recruitment to the brain in mouse and
human ischemic stroke</article-title>. <source>Acta Neuropathol
(Berl)</source>
<year>2015</year>; <volume>129</volume>:
<fpage>239</fpage>&#x02013;<lpage>257</lpage>.<pub-id pub-id-type="pmid">25548073</pub-id></mixed-citation></ref><ref id="bibr76-1756286418789854"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Del Zoppo</surname><given-names>GJ</given-names></name></person-group>
<article-title>Acute anti-inflammatory approaches to ischemic
stroke</article-title>. <source>Ann N Y Acad Sci</source>
<year>2010</year>; <volume>1207</volume>:
<fpage>143</fpage>&#x02013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">20955437</pub-id></mixed-citation></ref><ref id="bibr77-1756286418789854"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garcia</surname><given-names>JH</given-names></name><name><surname>Liu</surname><given-names>KF</given-names></name><name><surname>Bree</surname><given-names>MP.</given-names></name></person-group>
<article-title>Effects of CD11b/18 monoclonal antibody on rats with permanent
middle cerebral artery occlusion</article-title>. <source>Am J
Pathol</source>
<year>1996</year>; <volume>148</volume>:
<fpage>241</fpage>&#x02013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">8546211</pub-id></mixed-citation></ref><ref id="bibr78-1756286418789854"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>Chopp</surname><given-names>M</given-names></name><name><surname>Chahwala</surname><given-names>S.</given-names></name></person-group>
<article-title>Neutrophil inhibitory factor treatment of focal cerebral ischemia
in the rat</article-title>. <source>Brain Res</source>
<year>1998</year>; <volume>788</volume>:
<fpage>25</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">9554941</pub-id></mixed-citation></ref><ref id="bibr79-1756286418789854"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prestigiacomo</surname><given-names>CJ</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Connolly</surname><given-names>ES</given-names></name><etal>et al</etal></person-group>
<article-title>CD18-mediated neutrophil recruitment contributes
to the pathogenesis of reperfused but not nonreperfused
stroke</article-title>. <source>Stroke</source>
<year>1999</year>; <volume>30</volume>:
<fpage>1110</fpage>&#x02013;<lpage>1117</lpage>.<pub-id pub-id-type="pmid">10229752</pub-id></mixed-citation></ref><ref id="bibr80-1756286418789854"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krams</surname><given-names>M</given-names></name><name><surname>Lees</surname><given-names>KR</given-names></name><name><surname>Hacke</surname><given-names>W</given-names></name><etal>et al</etal></person-group>
<article-title>Acute Stroke Therapy by Inhibition of
Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute
ischemic stroke</article-title>. <source>Stroke</source>
<year>2003</year>; <volume>34</volume>:
<fpage>2543</fpage>&#x02013;<lpage>2548</lpage>.<pub-id pub-id-type="pmid">14563972</pub-id></mixed-citation></ref><ref id="bibr81-1756286418789854"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gee</surname><given-names>JM</given-names></name><name><surname>Kalil</surname><given-names>A</given-names></name><name><surname>Shea</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Lymphocytes: potential mediators of postischemic
injury and neuroprotection</article-title>. <source>Stroke</source>
<year>2007</year>; <volume>38</volume>(<issue>2 Suppl</issue>):
<fpage>783</fpage>&#x02013;<lpage>788</lpage>.<pub-id pub-id-type="pmid">17261738</pub-id></mixed-citation></ref><ref id="bibr82-1756286418789854"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hallenbeck</surname><given-names>J</given-names></name><name><surname>Del Zoppo</surname><given-names>G</given-names></name><name><surname>Jacobs</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Immunomodulation strategies for preventing
vascular disease of the brain and heart: workshop summary</article-title>.
<source>Stroke</source>
<year>2006</year>; <volume>37</volume>:
<fpage>3035</fpage>&#x02013;<lpage>3042</lpage>.<pub-id pub-id-type="pmid">17082471</pub-id></mixed-citation></ref><ref id="bibr83-1756286418789854"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Kipnis</surname><given-names>J.</given-names></name></person-group>
<article-title>Autoimmunity on alert: naturally occurring regulatory
CD4(+)CD25(+) T cells as part of the evolutionary compromise between a &#x000ab;
need &#x000bb; and a &#x000ab; risk &#x000bb;</article-title>. <source>Trends Immunol</source>
<year>2002</year>; <volume>23</volume>:
<fpage>530</fpage>&#x02013;<lpage>534</lpage>.<pub-id pub-id-type="pmid">12401405</pub-id></mixed-citation></ref><ref id="bibr84-1756286418789854"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llovera</surname><given-names>G</given-names></name><name><surname>Benakis</surname><given-names>C</given-names></name><name><surname>Enzmann</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>The choroid plexus is a key cerebral invasion
route for T cells after stroke</article-title>. <source>Acta Neuropathol
(Berl)</source>
<year>2017</year>; <volume>134</volume>:
<fpage>851</fpage>&#x02013;<lpage>868</lpage>.<pub-id pub-id-type="pmid">28762187</pub-id></mixed-citation></ref><ref id="bibr85-1756286418789854"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gelderblom</surname><given-names>M</given-names></name><name><surname>Weymar</surname><given-names>A</given-names></name><name><surname>Bernreuther</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Neutralization of the IL-17 axis diminishes
neutrophil invasion and protects from ischemic stroke</article-title>.
<source>Blood</source>
<year>2012</year>; <volume>120</volume>:
<fpage>3793</fpage>&#x02013;<lpage>3802</lpage>.<pub-id pub-id-type="pmid">22976954</pub-id></mixed-citation></ref><ref id="bibr86-1756286418789854"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liesz</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Mracsk&#x000f3;</surname><given-names>&#x000c9;</given-names></name><etal>et al</etal></person-group>
<article-title>Inhibition of lymphocyte trafficking shields the
brain against deleterious neuroinflammation after stroke</article-title>.
<source>Brain J Neurol</source>
<year>2011</year>; <volume>134</volume>(<issue>Pt 3</issue>):
<fpage>704</fpage>&#x02013;<lpage>720</lpage>.</mixed-citation></ref><ref id="bibr87-1756286418789854"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shichita</surname><given-names>T</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Ooboshi</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Pivotal role of cerebral
interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic
brain injury</article-title>. <source>Nat Med</source>
<year>2009</year>; <volume>15</volume>:
<fpage>946</fpage>&#x02013;<lpage>950</lpage>.<pub-id pub-id-type="pmid">19648929</pub-id></mixed-citation></ref><ref id="bibr88-1756286418789854"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liesz</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Na</surname><given-names>S-Y</given-names></name><etal>et al</etal></person-group>
<article-title>Boosting regulatory T cells limits
neuroinflammation in permanent cortical stroke</article-title>. <source>J
Neurosci Off J Soc Neurosci</source>
<year>2013</year>; <volume>33</volume>:
<fpage>17350</fpage>&#x02013;<lpage>17362</lpage>.</mixed-citation></ref><ref id="bibr89-1756286418789854"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liesz</surname><given-names>A</given-names></name><name><surname>Suri-Payer</surname><given-names>E</given-names></name><name><surname>Veltkamp</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Regulatory T cells are key cerebroprotective
immunomodulators in acute experimental stroke</article-title>. <source>Nat
Med</source>
<year>2009</year>; <volume>15</volume>:
<fpage>192</fpage>&#x02013;<lpage>199</lpage>.<pub-id pub-id-type="pmid">19169263</pub-id></mixed-citation></ref><ref id="bibr90-1756286418789854"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>mTOR signaling inhibition modulates
macrophage/microglia-mediated neuroinflammation and secondary injury via
regulatory T cells after focal ischemia</article-title>. <source>J Immunol
Baltim Md</source>
<volume>1950</volume>
<fpage>2014</fpage>; <volume>192</volume>:
<fpage>6009</fpage>&#x02013;<lpage>6019</lpage>.</mixed-citation></ref><ref id="bibr91-1756286418789854"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>B-L</given-names></name><etal>et al</etal></person-group>
<article-title>Adoptive regulatory T-cell therapy protects
against cerebral ischemia</article-title>. <source>Ann Neurol</source>
<year>2013</year>; <volume>74</volume>:
<fpage>458</fpage>&#x02013;<lpage>471</lpage>.<pub-id pub-id-type="pmid">23674483</pub-id></mixed-citation></ref><ref id="bibr92-1756286418789854"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Akiyoshi</surname><given-names>K</given-names></name><name><surname>Vandenbark</surname><given-names>AA</given-names></name><etal>et al</etal></person-group>
<article-title>CD4+FoxP3+ regulatory T-cells in cerebral
ischemic stroke</article-title>. <source>Metab Brain Dis</source>
<year>2011</year>; <volume>26</volume>:
<fpage>87</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21082336</pub-id></mixed-citation></ref><ref id="bibr93-1756286418789854"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stubbe</surname><given-names>T</given-names></name><name><surname>Ebner</surname><given-names>F</given-names></name><name><surname>Richter</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Regulatory T cells accumulate and proliferate in
the ischemic hemisphere for up to 30 days after MCAO</article-title>.
<source>J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow
Metab</source>
<year>2013</year>; <volume>33</volume>:
<fpage>37</fpage>&#x02013;<lpage>47</lpage>.</mixed-citation></ref><ref id="bibr94-1756286418789854"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kleinschnitz</surname><given-names>C</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Dreykluft</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Regulatory T cells are strong promoters of acute
ischemic stroke in mice by inducing dysfunction of the cerebral
microvasculature</article-title>. <source>Blood</source>
<year>2013</year>; <volume>121</volume>:
<fpage>679</fpage>&#x02013;<lpage>691</lpage>.<pub-id pub-id-type="pmid">23160472</pub-id></mixed-citation></ref><ref id="bibr95-1756286418789854"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liesz</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Kleinschnitz</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Functional role of regulatory lymphocytes in
stroke: facts and controversies</article-title>. <source>Stroke</source>
<year>2015</year>; <volume>46</volume>:
<fpage>1422</fpage>&#x02013;<lpage>1430</lpage>.<pub-id pub-id-type="pmid">25791715</pub-id></mixed-citation></ref><ref id="bibr96-1756286418789854"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Na</surname><given-names>S-Y</given-names></name><name><surname>Mracsko</surname><given-names>E</given-names></name><name><surname>Liesz</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Amplification of regulatory T cells using a CD28
superagonist reduces brain damage after ischemic stroke in
mice</article-title>. <source>Stroke</source>
<year>2015</year>; <volume>46</volume>:
<fpage>212</fpage>&#x02013;<lpage>220</lpage>.<pub-id pub-id-type="pmid">25378432</pub-id></mixed-citation></ref><ref id="bibr97-1756286418789854"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schuhmann</surname><given-names>MK</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Stoll</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>CD28 superagonist-mediated boost of regulatory T
cells increases thrombo-inflammation and ischemic neurodegeneration during
the acute phase of experimental stroke</article-title>. <source>J Cereb
Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab</source>
<year>2015</year>; <volume>35</volume>:
<fpage>6</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="bibr98-1756286418789854"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pham</surname><given-names>M</given-names></name><name><surname>Kleinschnitz</surname><given-names>C</given-names></name><name><surname>Helluy</surname><given-names>X</given-names></name><etal>et al</etal></person-group>
<article-title>Enhanced cortical reperfusion protects
coagulation factor XII-deficient mice from ischemic stroke as revealed by
high-field MRI</article-title>. <source>NeuroImage</source>
<year>2010</year>; <volume>49</volume>:
<fpage>2907</fpage>&#x02013;<lpage>2914</lpage>.<pub-id pub-id-type="pmid">19958838</pub-id></mixed-citation></ref><ref id="bibr99-1756286418789854"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Donnan</surname><given-names>GA</given-names></name><name><surname>Parsons</surname><given-names>MW</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of alteplase beyond 3 h after stroke in
the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a
placebo-controlled randomised trial</article-title>. <source>Lancet
Neurol</source>
<year>2008</year>; <volume>7</volume>:
<fpage>299</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="pmid">18296121</pub-id></mixed-citation></ref><ref id="bibr100-1756286418789854"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delgado-Mederos</surname><given-names>R</given-names></name><name><surname>Rovira</surname><given-names>A</given-names></name><name><surname>Alvarez-Sab&#x000ed;n</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Speed of tPA-induced clot lysis predicts DWI
lesion evolution in acute stroke</article-title>. <source>Stroke</source>
<year>2007</year>; <volume>38</volume>:
<fpage>955</fpage>&#x02013;<lpage>960</lpage>.<pub-id pub-id-type="pmid">17290028</pub-id></mixed-citation></ref><ref id="bibr101-1756286418789854"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gauberti</surname><given-names>M</given-names></name><name><surname>Vivien</surname><given-names>D.</given-names></name></person-group>
<article-title>Letter by Gauberti and Vivien regarding article, &#x000ab; amplification
of regulatory T cells using a CD28 superagonist reduces brain damage after
ischemic stroke in mice &#x000bb;</article-title>. <source>Stroke</source>
<year>2015</year>; <volume>46</volume>:
<fpage>e50</fpage>&#x02013;<lpage>e51</lpage>.<pub-id pub-id-type="pmid">25586834</pub-id></mixed-citation></ref><ref id="bibr102-1756286418789854"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gauberti</surname><given-names>M</given-names></name><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Quenault</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Molecular magnetic resonance imaging of
brain-immune interactions</article-title>. <source>Front Cell
Neurosci</source>
<year>2014</year>; <volume>8</volume>: <fpage>389</fpage>.<pub-id pub-id-type="pmid">25505871</pub-id></mixed-citation></ref><ref id="bibr103-1756286418789854"><label>103</label><mixed-citation publication-type="gov">
<collab>Min Lou</collab>. <source>Combinating fingolimod with alteplase bridging
with mechanical thrombectomy in acute ischemic stroke</source>, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02956200">https://clinicaltrials.gov/ct2/show/NCT02956200</ext-link>
(<year>2016</year>, <comment>accessed 15 May
2018</comment>).</mixed-citation></ref><ref id="bibr104-1756286418789854"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Impact of an immune modulator fingolimod on
acute ischemic stroke</article-title>. <source>Proc Natl Acad Sci U S
A</source>. <year>2014</year>; <volume>111</volume>:
<fpage>18315</fpage>&#x02013;<lpage>18320</lpage>.<pub-id pub-id-type="pmid">25489101</pub-id></mixed-citation></ref><ref id="bibr105-1756286418789854"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Combination of the immune modulator fingolimod
with alteplase in acute ischemic stroke: a pilot trial</article-title>.
<source>Circulation</source>
<year>2015</year>; <volume>132</volume>:
<fpage>1104</fpage>&#x02013;<lpage>1112</lpage>.<pub-id pub-id-type="pmid">26202811</pub-id></mixed-citation></ref><ref id="bibr106-1756286418789854"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudick</surname><given-names>R</given-names></name><name><surname>Polman</surname><given-names>C</given-names></name><name><surname>Clifford</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Natalizumab: bench to bedside and
beyond</article-title>. <source>JAMA Neurol</source>
<year>2013</year>; <volume>70</volume>:
<fpage>172</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">23128399</pub-id></mixed-citation></ref><ref id="bibr107-1756286418789854"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Kindrick</surname><given-names>D</given-names></name><name><surname>Relton</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Antibody to the alpha4 integrin decreases
infarct size in transient focal cerebral ischemia in rats</article-title>.
<source>Stroke</source>
<year>2001</year>; <volume>32</volume>:
<fpage>206</fpage>&#x02013;<lpage>211</lpage>.<pub-id pub-id-type="pmid">11136938</pub-id></mixed-citation></ref><ref id="bibr108-1756286418789854"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Langhauser</surname><given-names>F</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>G&#x000f6;b</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Blocking of &#x003b1;4 integrin does not protect from
acute ischemic stroke in mice</article-title>. <source>Stroke</source>
<year>2014</year>; <volume>45</volume>:
<fpage>1799</fpage>&#x02013;<lpage>1806</lpage>.<pub-id pub-id-type="pmid">24743435</pub-id></mixed-citation></ref><ref id="bibr109-1756286418789854"><label>109</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Riek-Burchardt</surname><given-names>M</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Very-late-antigen-4 (VLA-4)-mediated brain
invasion by neutrophils leads to interactions with microglia, increased
ischemic injury and impaired behavior in experimental
stroke</article-title>. <source>Acta Neuropathol (Berl)</source>
<year>2015</year>; <volume>129</volume>:
<fpage>259</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">25391494</pub-id></mixed-citation></ref><ref id="bibr110-1756286418789854"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Relton</surname><given-names>JK</given-names></name><name><surname>Sloan</surname><given-names>KE</given-names></name><name><surname>Frew</surname><given-names>EM</given-names></name><etal>et al</etal></person-group>
<article-title>Inhibition of alpha4 integrin protects against
transient focal cerebral ischemia in normotensive and hypertensive
rats</article-title>. <source>Stroke</source>
<year>2001</year>; <volume>32</volume>:
<fpage>199</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">11136937</pub-id></mixed-citation></ref><ref id="bibr111-1756286418789854"><label>111</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Llovera</surname><given-names>G</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Roth</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Results of a preclinical randomized controlled
multicenter trial (pRCT): anti-CD49d treatment for acute brain
ischemia</article-title>. <source>Sci Transl Med</source>
<year>2015</year>; <volume>7</volume>: <fpage>299ra121</fpage>.</mixed-citation></ref><ref id="bibr112-1756286418789854"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkins</surname><given-names>J</given-names></name><name><surname>Veltkamp</surname><given-names>R</given-names></name><name><surname>Montaner</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Safety and efficacy of natalizumab in patients
with acute ischaemic stroke (ACTION): a randomised, placebo-controlled,
double-blind phase 2 trial</article-title>. <source>Lancet Neurol</source>
<year>2017</year>; <volume>16</volume>:
<fpage>217</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">28229893</pub-id></mixed-citation></ref><ref id="bibr113-1756286418789854"><label>113</label><mixed-citation publication-type="gov">
<collab>Jake Elkins</collab>. <source>Safety and efficacy of intravenous
natalizumab in acute ischemic stroke</source>, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02730455">https://clinicaltrials.gov/ct2/show/NCT02730455</ext-link>
(<comment>accessed 31 May 2018</comment>.)</mixed-citation></ref><ref id="bibr114-1756286418789854"><label>114</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez de Lizarrondo</surname><given-names>S</given-names></name><name><surname>Gakuba</surname><given-names>C</given-names></name><name><surname>Herbig</surname><given-names>BA</given-names></name><etal>et al</etal></person-group>
<article-title>Potent thrombolytic effect of n-acetylcysteine
on arterial thrombi</article-title>. <source>Circulation</source>
<year>2017</year>; <volume>136</volume>:
<fpage>646</fpage>&#x02013;<lpage>660</lpage>.<pub-id pub-id-type="pmid">28487393</pub-id></mixed-citation></ref><ref id="bibr115-1756286418789854"><label>115</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orset</surname><given-names>C</given-names></name><name><surname>Haelewyn</surname><given-names>B</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name><etal>et al</etal></person-group>
<article-title>Efficacy of alteplase in a mouse model of acute
ischemic stroke: a retrospective pooled analysis</article-title>.
<source>Stroke</source>
<year>2016</year>; <volume>47</volume>:
<fpage>1312</fpage>&#x02013;<lpage>1318</lpage>.<pub-id pub-id-type="pmid">27032444</pub-id></mixed-citation></ref><ref id="bibr116-1756286418789854"><label>116</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orset</surname><given-names>C</given-names></name><name><surname>Macrez</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>AR</given-names></name><etal>et al</etal></person-group>
<article-title>Mouse model of in situ thromboembolic stroke and
reperfusion</article-title>. <source>Stroke</source>
<year>2007</year>; <volume>38</volume>:
<fpage>2771</fpage>&#x02013;<lpage>2778</lpage>.<pub-id pub-id-type="pmid">17702959</pub-id></mixed-citation></ref><ref id="bibr117-1756286418789854"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hossmann</surname><given-names>K-A.</given-names></name></person-group>
<article-title>The two pathophysiologies of focal brain ischemia: implications
for translational stroke research</article-title>. <source>J Cereb Blood
Flow Metab Off J Int Soc Cereb Blood Flow Metab</source>
<year>2012</year>; <volume>32</volume>:
<fpage>1310</fpage>&#x02013;<lpage>1316</lpage>.</mixed-citation></ref><ref id="bibr118-1756286418789854"><label>118</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Collins</surname><given-names>VE</given-names></name><name><surname>Macleod</surname><given-names>MR</given-names></name><name><surname>Donnan</surname><given-names>GA</given-names></name><etal>et al</etal></person-group>
<article-title>1,026 experimental treatments in acute
stroke</article-title>. <source>Ann Neurol</source>
<year>2006</year>; <volume>59</volume>:
<fpage>467</fpage>&#x02013;<lpage>477</lpage>.<pub-id pub-id-type="pmid">16453316</pub-id></mixed-citation></ref><ref id="bibr119-1756286418789854"><label>119</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spychala</surname><given-names>MS</given-names></name><name><surname>Honarpisheh</surname><given-names>P</given-names></name><name><surname>McCullough</surname><given-names>LD.</given-names></name></person-group>
<article-title>Sex differences in neuroinflammation and neuroprotection in
ischemic stroke</article-title>. <source>J Neurosci Res</source>
<year>2017</year>; <volume>95</volume>(<issue>1&#x02013;2</issue>):
<fpage>462</fpage>&#x02013;<lpage>471</lpage>.<pub-id pub-id-type="pmid">27870410</pub-id></mixed-citation></ref><ref id="bibr120-1756286418789854"><label>120</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Greter</surname><given-names>M</given-names></name><name><surname>Leboeuf</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Fate mapping analysis reveals that adult
microglia derive from primitive macrophages</article-title>.
<source>Science</source>
<year>2010</year>; <volume>330</volume>:
<fpage>841</fpage>&#x02013;<lpage>845</lpage>.<pub-id pub-id-type="pmid">20966214</pub-id></mixed-citation></ref><ref id="bibr121-1756286418789854"><label>121</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>G</given-names></name><name><surname>Granger</surname><given-names>DN.</given-names></name></person-group>
<article-title>Leukocyte recruitment and ischemic brain injury</article-title>.
<source>Neuro Molecular Med</source>
<year>2010</year>; <volume>12</volume>:
<fpage>193</fpage>&#x02013;<lpage>204</lpage>.</mixed-citation></ref><ref id="bibr122-1756286418789854"><label>122</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Felger</surname><given-names>JC</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Kaunzner</surname><given-names>UW</given-names></name><etal>et al</etal></person-group>
<article-title>Brain dendritic cells in ischemic stroke: time
course, activation state, and origin</article-title>. <source>Brain Behav
Immun</source>
<year>2010</year>; <volume>24</volume>:
<fpage>724</fpage>&#x02013;<lpage>737</lpage>.<pub-id pub-id-type="pmid">19914372</pub-id></mixed-citation></ref><ref id="bibr123-1756286418789854"><label>123</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>McCullough</surname><given-names>LD.</given-names></name></person-group>
<article-title>Middle cerebral artery occlusion model in rodents: methods and
potential pitfalls</article-title>. <source>J Biomed Biotechnol</source>
<year>2011</year>; <volume>2011</volume>:
<fpage>464701</fpage>.<pub-id pub-id-type="pmid">21331357</pub-id></mixed-citation></ref><ref id="bibr124-1756286418789854"><label>124</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hug</surname><given-names>A</given-names></name><name><surname>Dalpke</surname><given-names>A</given-names></name><name><surname>Wieczorek</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Infarct volume is a major determiner of
post-stroke immune cell function and susceptibility to
infection</article-title>. <source>Stroke</source>
<year>2009</year>; <volume>40</volume>:
<fpage>3226</fpage>&#x02013;<lpage>3232</lpage>.<pub-id pub-id-type="pmid">19661470</pub-id></mixed-citation></ref><ref id="bibr125-1756286418789854"><label>125</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veltkamp</surname><given-names>R</given-names></name><name><surname>Gill</surname><given-names>D.</given-names></name></person-group>
<article-title>Clinical trials of immunomodulation in ischemic
stroke</article-title>. <source>Neurother J Am Soc Exp Neurother</source>
<year>2016</year>; <volume>13</volume>:
<fpage>791</fpage>&#x02013;<lpage>800</lpage>.</mixed-citation></ref></ref-list></back></article>